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Abstract 
 
Curcumin, a dietary polyphenol, has been shown to have several preventive and 
therapeutic benefits in epidemiological studies. The chemopreventive potential of 
curcumin is related to its anti-inflammatory activity and is largely mediated through 
inhibition of the transcription factor NF-kB. However, curcumin has rather poor oral 
bioavailability (<1%). Much of orally dosed curcumin undergoes glucuronidation, 
resulting in the formation of inactive glucuronides. Thus, it is not clear how dietary 
curcumin exhibits chemopreventive activity despite not being absorbed into the systemic 
circulation in its active form. We proposed a prodrug hypothesis to explain this 
‘bioavailability paradox’ of curcumin. 
β-glucuronidase is an enzyme that hydrolyzes the glycosidic bond of 
glucuronides. Previous studies have shown that the expression of this enzyme is elevated 
under inflammatory conditions and overexpressed in necrotic regions of tumors. 
Increased β-glucuronidase activity in the tumor tissue in comparison to its relatively 
minimal activity in normal cells potentially explains the bioavailability paradox with 
curcumin. We hypothesized that curcumin glucuronide is an inflammation-responsive 
natural prodrug that gets converted back to curcumin ‘on-demand’ at the site of action.  
Our studies were aimed at determining specific activity of β-glucuronidase based 
on mammary tumor type, stage, and model. β-glucuronidase activity was determined in 
mammary tumor tissues with HER-2+ (BALB-neuT, TuBo) and triple negative (4T1, JC, 
MDA-MB-231) phenotypes. Activity assay results showed that the highest rate of 
conversion was in 4T1 tumors as compared to the other tumor types. 
	   vii 
Immunohistochemistry (IHC) studies on primary human breast tumor tissue samples 
showed β-glucuronidase expression levels to be highest in HER-2+ type breast cancer 
compared to triple negative and ER/PR+ types. Also determined from the microarray of 
human tissue samples, as well as from Western blotting and fluorescence imaging 
studies, was the strong correlation between enzyme expression levels and stage of cancer: 
normal and benign stages showed the lowest levels of β-glucuronidase while the 
invasive/metastatic stage showed the highest expression levels.  
Using a self-microemulsifying drug delivery system (SMEDDS) formulation that 
was developed to improve the oral absorption, we aimed next to investigate the 
chemopreventive efficacy of curcumin following oral administration. Daily oral dosing of 
curcumin for one month in the orthotopic models described above showed that those with 
higher β-glucuronidase specific activities (JC, MDA-MB-231, and 4T1) benefitted the 
most from curcumin in limiting tumor growth rate. Pharmacokinetic studies with oral 
dosing of curcumin SMEDDS showed elevated levels of the glucuronide metabolite in 
plasma as compared to negligible levels of curcumin while the trend was reversed in the 
tumor tissue, providing further support to the prodrug activation hypothesis. The 
pharmacokinetics of curcumin glucuronide following intravenous dosing also confirmed 
conversion of the glucuronide to the parent compound in the tumor tissue.   
Overall, the work presented in this thesis demonstrated the potential of oral 
curcumin for breast cancer chemoprevention based on the enzymatic prodrug activation 
hypothesis. 
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1.1 Physico-chemical Properties and Composition of Curcumin 
 Curcumin, a brilliant yellow-orange colored polyphenol, is the main bioactive 
ingredient extracted from the dried ground rhizome of the perennial herb Curcuma longa 
Linn (commonly known as turmeric), an herb of the curcuma species. Turmeric has been 
traditionally used for many centuries to give the distinctive flavor and color to curry 
spice, and curcumin has long been employed in traditional Indian and South Asian 
medicine (Ayurveda) for the treatment of a wide range of ailments. The molecular 
formula of curcumin is C21H20O6, and it has a molecular weight of 368.37 g/mol, melting 
point of 183 °C, and a predicted logP value of 3.62. Spectrophotometrically, the 
maximum absorption (λmax) of curcumin in methanol was observed to be at 430 nm and 
in acetone at 415-420 nm [1]. The polyphenol was first isolated in 1815 by Vogel and 
Pelletier [2], obtained in crystalline form in 1870 [2, 3], and its chemical structure of 
(1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione or diferuloyl-
methane was confirmed by Lampe and Milobedezka in 1910 [4]. The major 
curcuminoids, or chemically related structures to and derivatives of curcumin, in turmeric 
include curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Commercial 
curcumin consists of curcumin (77%), demethoxycurcumin (17%), and 
bisdemethoxycurcumin (3%) [5].  
Curcumin is an oil-soluble compound due to its hydrophobic nature, making it 
readily soluble in ethanol, methanol, acetone, dimethyl sulfoxide (DMSO), alkali, 
ketones, acetic acid and chloroform, and practically insoluble in water at acidic or neutral 
pH [4]. The compound can exist in both the enolic and beta diketone forms, with the enol 
form being more stable in solution and solid phase. In acidic pH conditions (≤ 6), 
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curcumin is relatively stable, but at neutral and basic pH (> 7), curcumin is rapidly 
degraded to ferulic acid and feruloylmethane, with vanillin being identified as a minor 
degradation product. However, one of the major metabolites of curcumin, 
tetrahydrocurcumin (THC), is stable at neutral and basic pH, but only for 1-2 hours [6]. 
Curcumin is a highly protein bound compound, making it more stable in cell culture 
medium containing protein such as 10% fetal bovine serum and in human blood [7].  
 
1.2 Molecular Targets and Mechanisms of the Therapeutic Benefits of Curcumin  
Deregulation of various cell signaling and transduction pathways because of 
alterations in a wide array of regulatory proteins is the key hallmark of cancer. Curcumin 
modulates and interacts with many regulatory proteins to modify their expression and 
activity, including inflammatory cytokines and enzymes, transcription factors, growth 
factors, and gene products that are associated with cell survival, proliferation, invasion, 
and angiogenesis. Studies have found that curcumin inhibits several signaling pathways 
and molecular targets involved in cancer progression and inflammation. This was 
observed from documentation of curcumin inhibiting proliferation and growth of various 
tumor cells in culture, and limiting the growth rate of human tumors xenografted in 
animal models. The various molecular targets of curcumin which are involved in several 
cell signaling pathways are presented in the following. 
Curcumin is known to inhibit the activation of several transcriptional factors, 
including activator protein (AP)-1, nuclear factor-kappa B (NF-κB), β-catenin, early 
growth response gene (EGR)-1, signal transducers and activators of transcription 
(STAT)-3, hypoxia inducible factor (HIF)-1, and Notch-1, which are all upregulated in 
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cancer. Such transcription factors play a role in cell proliferation, invasion, metastasis, 
and angiogenesis. Studies have shown curcumin to inhibit both inducible and constitutive 
STAT3 activation and its nuclear translocation by inhibiting Janus kinase (JAK)-2 
phosphorylation in several myeloma cell lines [8]. Constitutive STAT3 activation was 
also inhibited in peripheral blood mononuclear cells from myeloma and pancreatic cancer 
patients [9, 10]. In AP-1 signaling, curcumin has been observed to inhibit AP-1 activation 
by tumor promoters, which in turn inhibits C-Jun N-terminal kinase (JNK) activation by 
carcinogens [11, 12]. Notch-1 signaling, which cross-talks with another important cell 
growth and apoptotic pathway (NF-κB), is also limited due to curcumin-induced 
reductions in Notch-1 levels [13]. Wnt/β-catenin signaling, a pathway that is important in 
tissue development, homeostasis, and regeneration and often deregulated in human 
cancer, is inhibited by reducing levels of β-catenin and Tcf-4 proteins, as shown in 
studies with gastric, colon and intestinal cancer cell lines [14, 15]. It has been also shown 
that curcumin suppresses the induction of transcription factor Egr-1, a gene regulator in 
vasculature growth, differentiation, wound healing, blood clotting, and immune response. 
This suppression of Egr-1 by curcumin modulates the Egr-1 gene in fibroblasts, 
endothelial cells [16], and colon cancer cells [17]. 
NF-κB is a major transcription factor that is modulated by curcumin. NF-κB 
mainly serves as a gene regulator that controls cell proliferation and cell survival. The 
NF-κB heterodimer – NF-κB complexed with the inhibitory protein IκBα – exists in the 
cytosol in an inactivated state. Extracellular signals stimulate and activate the enzyme 
IκB kinase (IKK) through integral membrane receptors, causing IKK to phosphorylate 
and thus mark the IκBα protein for dissociation and degradation [18]. The activated NF-
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κB then translocates to the nucleus where it may bind to response elements (RE) at 
certain sequences of DNA and therefore initiate transcriptional activity for cell survival 
[19]. Curcumin inhibits NF-κB signaling and induces apoptosis by inhibiting IKK 
signaling and phosphorylation of IκBα, causing NF-κB to remain bound to inhibitory 
IκBα [20].  
Not only does curcumin inhibit IKK signaling, but it also inhibits inflammatory 
cytokines such as interleukins and tumor necrosis factor-alpha (TNF-α). TNF-α plays key 
roles in immunity, cellular remodeling, apoptosis, and cell survival [21]. Since TNF-α is 
also largely responsible for the cause of inflammation, many efforts have been put forth 
to develop antagonists for the receptors of TNF-α in the treatment of inflammation and 
cancer. Curcumin has significant activity against TNF-α-induced signaling, as it not only 
modulates the signaling, but also inhibits the expression of the cytokine. It is known to 
inhibit expression of TNF-α mRNA in rat livers with CCl4-induced hepatic fibrosis [22]. 
Curcumin reduced TNF-α levels in sodium taurocholate-induced acute pancreatitis in rats 
[23], diabetic encephalopathy in rats, and cisplatin-induced nephrotoxicity in mice [24]. 
In addition, curcumin has been shown to be a potent inhibitor of interleukins as well, a 
class of pro-inflammatory cytokines that are involved in the induction of 
metalloproteinases, adhesion molecules, and pro-angiogenic factors [25]. Studies have 
shown curcumin to inhibit IL-1 [26], IL-2 [27], IL-5 [28], IL-8 [26], IL-12 [29], and IL-
18 [30] expression. In one study, curcumin inhibited IL-6-induced phosphorylation of 
STAT3 in myeloma cells [8].  
 The mitogen-activated protein kinase (MAPK) and PI3K/Akt/mTOR cellular 
signaling pathways are other pathways that curcumin modulates. MAPKs play important 
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roles in converting various extracellular signals into intracellular responses via serial 
phosphorylation cascades [31]. Environmental stress stimuli such as cytokines (TNF-α, 
interleukins), ultraviolet (UV) light, and ionizing radiation induce activation of MAPKs 
(ERK, JNK, and p38), which can in turn phosphorylate transcription factors that include 
c-myc, c-jun, Sin1-associated protein (SAP-1), GADD153, myocyte enhancer factor-2C 
(MEF2C), and activating transcription factor-2 (ATF2), thus eventually causing 
alterations in gene expression [32-34]. Regulation of MAPK signaling by curcumin has 
been shown to contribute to suppression of tumorigenesis and inflammation. Studies have 
reported curcumin inhibiting the upregulation of COX-2 and MMP-9 by blocking 
ERK1/2 phosphorylation in MCF10A human breast epithelial cells [35]. In addition, JNK 
activation was inhibited by curcumin in human Jurkat T (leukemia) cells and human 
embryonic kidney 293 cells [36]. This inhibition of several signaling modules by 
curcumin in the MAPK cascade enhances the induction of apoptosis in both in vitro and 
in vivo tumor models [37]. 
 The PI3K/Akt/mTOR signaling pathway is a key regulator of the cell cycle, 
survival, and apoptosis. There have been several reports of curcumin inducing apoptosis 
in cancer cells due to the inhibition of multiple components in the PI3K/Akt/mTOR 
pathway. One key component that is modulated is the dephosphorylation of Akt, as 
observed with acute T-cell leukemia [38]. Since Akt is a protein kinase that promotes cell 
survival by phosphorylating Bcl-2-associated agonists of cell death, curcumin limits B 
lymphoma cell growth by inhibitng Akt and its target genes [39]. Levels of 
phosphorylated Akt, an indication of activated Akt, dramatically decreased as a response 
to receiving high doses of curcumin [40]. Additionally, PI3K/Akt/mTOR signaling is 
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stimulated by activation of membrane receptors, such as EGFR, via external cytokines 
and growth factors. Curcumin functions to not only inhibit EGF-stimulated 
phosphorylation of Akt, but the polyphenol also limits the levels of the cytokines 
themselves that are stimulating membrane receptors in breast cancer cells and thereby 
facilitate the induction of apoptosis [41]. 
 Curcumin is known to modulate the activity of enzymes that are involved in 
inflammation and cancer, including cyclooxgenase-2 (COX-2), matrix metalloproteinases 
(MMPs), and inducible nitric oxide synthase (iNOS). Overexpression of COX-2 has been 
linked with many types of cancers, including that of the colon, lung, and breast. 
Cycolooxygenase is an enzyme that converts arachidonic acid to prostaglandins and 
thromboxanes, and COX-2 specifically is overexpressed at inflammatory sites, which 
may play a critical role in tumor promotion and tumorigenesis. Studies have 
demonstrated that curcumin inhibits COX-2, the inducible form of COX, but not COX-1, 
the constitutively active form of COX that is responsible for homeostatic functions [42]. 
This effect is due mainly to the inhibition of the IKK signaling complex in the NF-κB 
pathway to phosphorylate inhibitory IκBα, and thereby blocking the activation of NF-κB 
[43]. Curcumin was shown to inhibit COX-2 initiation by the colon tumor promoter TNF-
α due to inhibition of NF-κB activation in human colon epithelial cells [44]. In addition, 
it has been reported that curcumin also suppressed the chenodeoxycholate-(CDC) or 
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) mediated induction of COX-2 
and inhibited synthesis of prostaglandin E2 in several gastrointestinal cell lines [45]. 
Expression of COX-2 in peripheral blood mononuclear cells from pancreatic cancer [10] 
and myeloma [9] patients was inhibited by curcumin. A specific inhibitor of COX-2, 
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Celecoxib, is approved by the Food and Drug Administration (FDA) for the treatment of 
inflammatory conditions.  
 Matrix metalloproteinases (MMPs) are endopeptidases, which are overexpressed 
in tumor infiltration. MMP-2 and MMP-9 are mainly associated with tumor angiogenesis 
via their roles of extracellular matrix (ECM) degradation [46]. It has been demonstrated 
that curcumin limits the invasion and metastasis of cancer cells through suppression of 
MMPs. Inhibition of TPA-induced ERK activation and NF-κB transcriptional activation 
in human breast cancer epithelial cells by curcumin has been reported [36]. Curcumin 
downregulates MMP-9 expression, which is associated with brain tumors, by inhibiting 
NF-κB and AP-1 binding to the DNA promoter region [47]. It has been also shown that 
curcumin inhibits expression of MMP-9 in orthotopically transplanted pancreatic [48] 
and ovarian [49] tumors in nude mouse models. Moreover, iNOS, another enzyme 
associated with inflammation and metastasis, is also inhibited by curcumin, as was the 
case in inhibiting its production in in vitro cultured Balb/c mouse peritoneal macrophages 
[11, 50].    
Cytokine signaling receptors and growth factors are also molecular targets of 
curcumin. Suppression of the expression of growth factors such as EGF, HER-2, FGF, 
VEGF, TNF-α, insulin growth factor (IGF-1), and their receptors is essential in 
suppressing tumor growth. Numerous reports exist of curcumin being a key modulator in 
the expression and activity of these various growth factors. Epidermal growth factor 
receptor (EGFR) is overexpressed in several tumor types, including lung, head and neck, 
colorectal, and breast cancer, and curcumin has been shown to inhibit EGFR1 
overexpression [11, 12]. HER-2, another member of the EGFR class, is also 
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overexpressed in many cancers. While Trastuzumab (trade name: Herceptin®) is 
currently one of the main FDA approved antagonists for the treatment of HER-2+ breast 
cancer, curcumin has shown promising results in inhibiting HER-2 overexpression in 
A431 cells [51]. There is evidence that curcuminoids modulate the fibroblast growth 
factor (FGF-2) angiogenic signaling pathway as well as inhibit expression of vascular 
endothelial growth factor (VEGF), thus limiting angiogenesis and tumor growth. 
Bevacizumab (trade name: Avastin®) is the only VEGF inhibitor approved by the FDA 
for the treatment of non-small cell lung cancer, and studies have shown that curcumin 
inhibited VEGF expression levels in NIH3T3 cells and transcript levels of two major 
angiogenesis factors, VEGF and bFGF, in the triple negative MDA-MB-231 breast 
cancer cells [52, 53] at similar levels as Avastin. Curcumin also inhibited VEGF 
expression in orthotopically implanted ovarian [49] and pancreatic tumors [48] in nude 
mouse models. Furthermore, expression and activation of hormone (estrogen, 
progesterone) receptors (ER/PR) are also suppressed by curcumin. Estrogen and estrogen 
receptors alpha and beta (ER-α and ER-β) play a major role in tumorigenesis, as two-
thirds of breast cancers are associated with overexpression of these functional receptors. 
Studies have reported that curcumin not only inhibits proliferation of ER-positive cells, 
but also ER-negative cells as well (i.e., breast adenocarcinoma cells of the triple negative 
subtype), which suggests that curcumin has chemopreventive effects in both an ER-
dependent and ER-independent manner [54].  
Other effects on molecular targets include activating pro-apoptotic caspases, 
downregulating anti-apoptotic proteins such as Bcl-2 and Bcl-XL, upregulating tumor 
suppressor p53, and suppressing the expression of cyclin D1. Studies have revealed 
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curcumin to induce cytotoxicity and apoptosis via caspase-3 activation in human colon 
cancer cells, promoting expression of tumor suppressor protein p53 and inhibiting 
expression of anti-apoptotic Bcl-2 and Bcl-XL proteins [55]. Curcumin induces apoptosis 
in human malignant mesothelioma cells and human mantle cell lymphoma by 
downregulating Bcl-2 and Bcl-XL expression [56]. In addition, p53, a tumor suppressor 
protein that plays a pivotal role in cell cycle control, genomic stability, cellular response 
to DNA damage, signal transduction and apoptosis, is upregulated by curcumin [57]. As a 
tumor suppressor, functional p53 activates transcription of downstream genes such as 
p21cip1/waf-1 and p27kip-1 to induce apoptosis, inhibit the growth of DNA damaged cells, 
and block cell cycle progression [58]. Curcumin serves to upregulate p53 gene 
expression, as seen in the growth arrest and induction of apoptosis in BKS-2 cell 
lymphoma [59], human melanoma [60], and glioma [61] cells. Moreover, cyclin D1, a 
component of the subunit of cyclin-dependent kinase CDK4 and CDK6, is overexpressed 
in a variety of tumor cells, thus causing alterations and deregulation in cell cycle 
progression. Curcumin has been known to inhibit cyclin D association with CDK4/CDK6 
and phosphorylate tumor suppressor pRb, which blocks cell cycle progression from G1 to 
S phase [62]. Through upregulation of CDK inhibitors (CDKIs) and downregulation of 
cyclin B1 and cdc2, curcumin induces G0/G1 or G2/M phase cell cycle arrest in 
umbilical vein endothelial (ECV304) cells [63]. Downregulation of cyclin D1 in vivo was 
observed to be at both the transcriptional and translational levels. 
The ability of curcumin to inhibit several signaling pathways and modulate 
molecular targets that are key to tumorigenesis and inflammation, in combination with 
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minimal systemic cytotoxicity and side effects at high oral doses, suggests the high 
potential of this polyphenol to be widely used as a chemopreventive compound. 
 
1.3 Curcumin for Chemoprevention 
 Curcumin has several pharmacological effects that make it an excellent candidate 
for use in cancer chemoprevention. The compound itself is safe and relatively non-toxic 
when ingested orally. It has been shown that large doses of curcumin administered orally 
for extended periods of time is safe – no significant toxicity was observed in pilot phase I 
clinical trials in healthy human volunteers who consumed daily doses of up to 12 grams 
of curcumin orally for 3 months [73]. Cytotoxicity primarily occurs with diseased tissue 
and cells, as curcumin regulates and restores several signaling pathways that contribute to 
cancer. Downregulation of overexpressed proteins and cytokines, such as interleukins and 
tumor necrosis factor-α (TNF-α), as well as various growth factors also play a key role in 
tumor cell cytotoxicity [74]. Since curcumin is a common and naturally occurring 
compound that mainly functions by intervening with only abnormal cellular processes, it 
is a strong candidate for being widely used as a chemopreventive agent.  	  
1.4 Bioavailability of Curcumin 
Numerous pre-clinical studies and phase I clinical trials have shown that 
curcumin possesses diverse pharmacological effects, but exhibits poor bioavailability 
(<1%). Low plasma and tissue levels of curcumin are attributed to its poor absorption 
along the gastrointestinal tract, extensive first-pass metabolism in the liver, and rapid 
elimination from the body. The lipophilicity and low aqueous solubility of curcumin 
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limits its rate of dissolution in the gastrointestinal tract upon oral administration, and 
hence a greater portion of the dose remains unabsorbed and is excreted. It has been 
reported that very low levels of curcumin were present in serum after oral dosing, a 
strong indication of low bioavailability. In a study involving the intravenous dosing of 
rats with curcumin at 10 mg/kg, the maximum concentration observed in serum was 0.36 
± 0.05 µg/mL, whereas a 500 mg/kg dose (50-fold higher than IV dose) administered 
orally yielded only 0.06 ± 0.01 µg/mL at maximum serum levels [70]. For rats, the 
maximum serum concentration of curcumin at 45 minutes after an oral dose at 1 g/kg was 
0.5 µg/mL [77]. Another study reported that at 50 minutes after an oral dose of curcumin, 
the maximum concentration was found to be only 6.5 ± 4.5 ng/mL [78].  
In addition to poor absorption, curcumin undergoes rapid first-pass metabolism as 
well, both within the enterocytes along the gastrointestinal wall immediately upon 
absorption and in the hepatocytes of the liver, where a significant portion of the absorbed 
curcumin is either sulfonated or glucuronidated by phase II metabolism. Studies have 
reported that gut bacteria play a role in phase I metabolism of curcumin [79]. It has been 
shown that the NADPH-dependent curcumin/dihydrocurcumin reductase (CurA) enzyme 
originating from Escherichia coli (E. coli) present in the gastrointestinal tract metabolizes 
curcumin in a two step-reduction, first to intermediate dihydrocurcumin (DHC), and then 
to the end product tetrahydrocurcumin (THC). Some studies have observed THC and 
other reduced curcumin metabolites to possess even greater potency than curcumin in 
terms of anti-inflammatory [80], antidiabetic, and antihyperlipidemic [81] activity, as 
well as equal potency in terms of antioxidant activity [82]. Moreover, phase II 
metabolism of curcumin also contributes to its low bioavailability. Sulfonation and 
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glucuronidation of curcumin in the first-pass effect of the liver yields inactive conjugated 
metabolites of the polyphenolic compound in the systemic circulation.  
Several approaches have been developed and studied in attempts to increase the 
bioavailability of curcumin. Concomitant administration of adjuvants has been used to 
inhibit metabolic pathways as major means of improving its bioavailability. In one study, 
it was noted that the effects of piperine, a known inhibitor of intestinal and hepatic 
glucuronidation, when co-administered with curcumin, effectively increased the 
bioavailability of curcumin by 2000% [83]. Additionally, other novel formulations that 
have been studied and showed promising results in increased curcumin bioavailability 
and delivery include nanoparticles [84-85], micelles [86-87], liposomes [88-90], and 
phospholipid complexes [91-92]. 
In the studies presented in this thesis, a self-microemulsifying drug delivery 
system (SMEDDS) formulation (see below) was developed to enhance the solubility of 
curcumin and thus improve the bioavailability of oral curcumin.  	  
1.5 Pharmacokinetics of Curcumin 
 Numerous studies have investigated the pharmacokinetics of curcumin following 
oral, intravenous (IV), and intraperitoneal (IP) dosing, revealing its poor absorption and 
rapid elimination from the body. When curcumin powder is administered orally, low 
levels of curcumin have been found in the plasma and a major fraction of the dose is 
excreted unchanged in the feces. In rats, a 400 mg oral dose of curcumin resulted in 40% 
of the dose to be eliminated unchanged in the feces with no detectable levels in the urine 
and heart blood, and only trace levels in the portal blood and kidneys. The same study 
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showed 90% of the curcumin remaining in the gastrointestinal tract 30 minutes after 
administration, and only 1% remaining in the kidneys after 24 hours post-dose [64]. 
Another study reported negligible levels of curcumin in plasma of rats following oral 
administration of 1 g/kg of curcumin, indicating poor absorption of the drug from the gut 
[65]. In studies with mice, an IP dose of 100 mg/kg resulted in 2.25 µg/mL of curcumin 
in the plasma within the first 15 minutes of dosing. In the same study, at 1 hour post IP 
dose, curcumin levels in the intestine, spleen, liver, kidneys, and brain had levels of 
177.04, 26.06, 26.09, 7.51, and 0.41 µg/g, respectively [66].  
 Clinical trials in human subjects further revealed the low levels of curcumin in 
plasma following oral administration. In Taiwan, 25 patients with cancer lesions were 
administered varying doses of 4, 6, and 8 grams of curcumin per day. After treatment for 
3 months, peak serum concentrations were found to be 0.51 ± 0.11, 0.64 ± 0.06, and 1.77 
± 1.87 µM, respectively. Lower doses resulted in undetectable levels in the serum [67]. In 
another clinical study with colorectal cancer patients, 1.8 g and 3.6 g of curcumin were 
administered orally for seven days, resulting in serum concentrations of 7.7 ± 1.8 and 
12.7 ± 5.7 nmol/g, respectively [68]. After an IP dose of 100 mg/kg curcumin in human 
patients, intestinal tissue levels reached 300 nmol/g, as compared to 1 nmol/g in the brain 
and 72 nmol/g in the liver [69].  
 Distribution of curcumin in tissue and elimination from the body are important 
factors in its pharmacological activity. Studies investigating curcumin distribution have 
used 14C curcumin as a method to measure curcumin levels in various tissues. In an in 
vivo study with C57B1/6J mice, a single IP dose of 100 mg/kg 14C curcumin resulted in 
the following observed peak drug concentrations: intestine: 200 ± 23 nmol/g, liver: 73 ± 
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20 nmol/g, brain 2.9 ± 0.4 nmol/g, heart: 9.1 ± 1.1 nmol/g, lung: 16 ± 3 nmol/g, kidney: 
78 ± 3 nmol/g, and muscle: 8.4 ± 6.0 nmol/g. In the same study, radioactivity of 14C 
declined rapidly after reaching between 20 – 33% of the peak values at 4 or 8 hours post-
dose [72]. Other studies have determined the elimination half-life values of curcumin for 
an IV dose of 10 mg/kg in rats to be 28.1 ± 5.6 hours and for an oral dose of 500 mg/kg 
to be 44.5 ± 7.5 hours [70]. 
 
1.6 Clearance of Curcumin 
In addition to being poorly absorbed following oral administration, curcumin also 
undergoes extensive metabolism in both the enterocytes of the gastrointestinal wall and 
the hepatocytes of the liver. Both phase I (reduction) and phase II (conjugation) 
metabolic pathways play prominent roles in limiting its bioavailability.  
 
1.6.1 Phase I Metabolism 
 Phase I metabolism involves the formation of a new or modified functional group 
or cleavage, such as in the case of oxidation, reduction, and hydrolysis reactions. Such 
reactions are non-synthetic, and typically consist of conversion of a parent drug to a more 
polar metabolite by the insertion of a polar functional group. Curcumin is readily reduced 
to dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, and octahydrocurcumin 
upon IV and IP administration [93]. These reduction reactions are catalyzed primarily by 
alchohol dehydrogenase in the liver. In vitro studies have confirmed the phase I 
metabolism of curcumin, as evidenced by reductive metabolite levels being prominent 
following incubation of curcumin with precision-cut liver slices from rats. In one in vitro 
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study, curcumin incubated with Sprague-Dawley rat liver slices yielded five reductive but 
no oxidative metabolites, and the major reductive metabolites were 
hexahydrocurcuminoids [94]. In addition, incubating curcumin with pure alchohol 
dehydrogenase enzyme yields significant levels of reduced metabolite products, further 
confirming that these products are in fact due to phase I metabolism. It has also been 
observed that many of the reduced phase I metabolites of curcumin are further 
metabolized and undergo phase II conjugation metabolism.  
 
1.6.2 Phase II Metabolism 
 Phase II metabolism consists of conjugating the active drug compound with an 
endogenous substance, such as glucuronic acid, sulfate, or glycine. These reactions are 
synthetic and result in a metabolite that has higher molecular weight, higher polarity, and 
less activity than the parent drug. Due to the higher polarity of the metabolite, phase II 
metabolites are more readily excreted through the kidneys.  
 Curcumin is either glucuronidated by UDP-glucuronosyltransferases (UGTs) or 
sulfated by sulfotransferases (SULTs). There exist numerous isoforms of both UGTs and 
SULTs, but only a select few are important to curcumin metabolism. UGT1A1 and 
UGT1A3 isozymes, both specific to the liver, account for the highest activity of curcumin 
glucuronidation, as has been shown using recombinant UGTs. Intestinal UGT1A8 and 
UGT1A10 predominantly catalyze the glucuronidation reaction in the enterocytes along 
the gut wall [95]. One in vivo study showed that following oral dosing, 99% of curcumin 
in the plasma was present as curcumin glucuronide [96]. While the four isoforms of UGT 
mentioned above are mainly responsible for the glucuronidation of curcumin, metabolic 
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activity levels vary between human and rodent microsomes, and by whether it is taking 
place in the intestine or the liver. Enzymatic activity levels were shown to be similar 
between human hepatic (4641 ± 126 pmol/min/mg protein) and rat hepatic (4589 ± 170 
pmol/min/mg protein) microsomes, but the levels of human intestinal metabolic activity 
by UGTs (12687 ± 1138 pmol/min/mg protein) is approximately 3-fold higher as 
compared to rat intestinal enzyme activity (3933 ± 104 pmol/min/mg protein) [97]. Such 
differences between species in metabolic activity must be taken into account when 
translating from pre-clinical trials involving animal models to clinical trials involving 
human patients. In another study, it has been shown that glucuronidation accounts for 
~82% of all metabolites observed. Sulfonation, mediated by SULT1A1 and 1A3, account 
for the remainder of the fraction of phase II curcumin metabolism (~15%) [98]. Overall, 
curcumin undergoes extensive phase II metabolism via glucuronidation and sulfonation, 
which contributes greatly to its limited bioavailability of reaching the systemic 
circulation in its active form.  
 
1.7 Bioavailability Paradox 
Curcumin is known to have a wide range of preventive and therapeutic effects, 
and has been employed for the treatment of diseases and ailments that range from 
digestive, hepatic, and biliary disorders, to wound healing, sinusitis, rheumatism, and 
inflammation. Pharmacologically, curcumin has been shown to have anti-cancerous, anti-
proliferative, anti-oxidant, and anti-inflammatory properties in numerous studies on both 
the pre-clinical and clinical levels. Reports of southern Asia – a region of the world in 
which Indian curry spice containing curcumin is prevalent in regular dietary consumption 
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– having some of the lowest rates of colorectal and lung cancer [176] have further 
supported the idea that the polyphenol has chemopreventive effects. 
Though curcumin possesses many health benefits and has demonstrated its 
preventive and therapeutic potential when administered orally, less than 1% of orally 
administered curcumin is bioavailable because of its poor intestinal absorption and 
extensive metabolism. A majority of the curcumin absorbed undergoes rapid 
glucuronidation in the intestinal wall or the liver, and thus yielding the inactive 
metabolite curcumin glucuronide as the primary form present in systemic circulation. 
Thus, it is unclear how dietary curcumin exhibits chemopreventive activity despite not 
being absorbed into the systemic circulation in its active form. The objectives of this 
thesis is to investigate the mechanisms behind this ‘bioavailability paradox’ by 
determining the pharmacokinetics of curcumin and its metabolite curcumin glucuronide 
as well as anticancer efficacy following the oral administration of curcumin in a 
microemulsion formulation that improves its oral absorption.  
 
1.8 Prodrug Hypothesis 
 The prodrug activation hypothesis is a proposal for the mechanism of 
chemopreventive action of oral curcumin. It proposes to explain the ‘bioavailability 
paradox’ of curcumin, in which despite its poor bioavailability, oral curcumin has been 
repeatedly shown to have several preventive and therapeutic benefits. When curcumin is 
orally administered and reaches the gastrointestinal tract (GIT), curcumin is absorbed 
along the GIT, which is then delivered to the liver via the hepatic portal vein. Curcumin 
undergoes phase II metabolism by UDP-glucuronosyltransferases (UGTs) in either the 
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enterocytes along the gastrointestinal wall or the hepatocytes of the liver to form 
curcumin glucuronide. The inactive metabolite curcumin glucuronide is the predominant 
form that circulates in plasma. Curcumin glucuronide that reaches a site of inflammation 
or tumor in which the enzyme β-glucuronidase is overexpressed would then be converted 
back to active curcumin at the site of action. Minimal to no activation in healthy tissue 
with marginal enzyme expression is expected. Any metabolite remaining in the systemic 
circulation would be cleared by renal filtration due to its high water solubility and low 
cell permeability. In essence, oral curcumin is metabolized in either the gastrointestinal 
wall or liver to curcumin glucuronide, followed by subsequent activation back to active 
curcumin by β-glucuronidase at the site of disease or inflammation.  
The prodrug activation hypothesis ultimately suggests that curcumin glucuronide 
is an inflammation-responsive natural prodrug that gets converted back to curcumin ‘on-
demand’ at the site of action. Curcumin glucuronide is deconjugated by β-glucuronidase 
present in the tumor tissue and sites of inflammation to generate the active parent 
compound curcumin, which can then exert its pharmacological effects at the target site 
(Figure 1.1). 
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Figure 1.1. Schematic of the prodrug activation hypothesis. Oral curcumin is 
metabolized either in the gastrointestinal wall upon absorption or liver to curcumin 
glucuronide, which predominates in plasma circulation. Curcumin glucuronide is 
activated by β-glucuronidase in sites of disease or inflammation to active curcumin. 
Remaining curcumin glucuronide is eliminated by renal filtration.  
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 Based on previous reports and data presented in this thesis, we propose that the 
prodrug activation hypothesis is the main mechanism of curcumin chemopreventive 
action. The lipophilic nature of curcumin that is activated from curcumin glucuronide in 
the tumor would allow for accumulation within the disease tissue. This key chemical 
property that allows for such accumulation within the tumor microenvironment is 
essential in the therapeutic efficacy of curcumin. Slow but steady accumulation over time 
increases the concentration of active curcumin at the site of action, and therefore greater 
efficacy from higher levels of the active drug. 
It has been previously reported in literature that steady, regular low doses of drug 
being administered over a period of time is a more effective therapeutic approach than 
single, high-dose treatments [75, 76]. This may very well be due to the accumulation of 
lipophilic drug in the tissue that occurs over time, in which a higher concentration of drug 
leads to an increased efficacy and more effective treatment. Single, high-dose treatments 
may not be effective due to the pharmacokinetics of the drug, in that although there may 
be a higher maximum concentration of drug in plasma or site of action immediately after 
administration, these levels would unlikely be maintained for long due to drug clearance. 
The concept of “metronomic chemotherapy” describes this phenomenon, in which tumor 
growth inhibition occurs by administering regular and consistent, low-dose 
chemotherapy. Even though conventional high-dose chemotherapy directly kills tumor 
cells, side effects are often a major issue with such dosage regimens. While further 
studies are necessary, a sustained and near-constant maintenance of drug levels in the 
systemic circulation through regular, low dosages would be a more desired approach both 
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in the aspects of limiting systemic toxicity and maximizing efficacy through drug 
accumulation [75, 76]. 
This concept of “metronomic therapy” applies to the prodrug activation 
hypothesis of chemoprevention by curcumin as well. Regular, daily oral doses of 
curcumin would yield steady and near-constant concentrations of curcumin glucuronide 
in the plasma. While administered doses of curcumin may be low or sub-therapeutic, the 
steady metabolism of curcumin to curcumin glucuronide would generate sufficient levels 
of the metabolite in the circulation. These low levels of curcumin glucuronide would be 
activated by β-glucuronidase at inflammation sites, causing a slow but steady 
accumulation of curcumin. It is a combination of the moderate and regular activation of 
curcumin glucuronide in disease sites overexpressing β-glucuronidase plus the lipophilic 
nature of curcumin that would ultimately contribute to its accumulation in the tumor, 
which is essential in successful chemoprevention.  
 
1.9 Curcumin Glucuronide as a Natural Prodrug 
A prodrug is a bioreversible derivative of a drug molecule that undergoes an 
enzymatic and/or chemical transformation in vivo to release the active parent drug, which 
can exert the desired pharmacological effect at the target site of action [99, 100]. 
Prodrugs are typically inactive until activated through certain catabolic processes. One 
example of such an activation reaction is the hydrolysis of an ester. The purpose of 
formulating a prodrug is to enhance the bioavailability and pharmacokinetics of a drug, in 
which the absorption, distribution, metabolism, and/or excretion (ADME) is modified to 
improve drug delivery [101, 102]. They may also be used to improve selectivity of the 
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drug to a specific target site of action, or reduce adverse or unintended side effects of a 
drug. This is particularly important in chemotherapy treatments where undesirable side 
effects are often caused by non-specific cytotoxicity.   
Curcumin glucuronide serves as a natural prodrug in that orally administered 
curcumin undergoes rapid phase II metabolism and is conjugated with a glucuronide 
promoiety by natural metabolic processes. Due to this metabolism and the hydrophilic 
nature of the glucuronide, curcumin glucuronide is the main form of curcumin that is 
present in systemic circulation, and not active curcumin itself. The glucuronide would 
circulate in plasma and upon reaching a site of disease or inflammation that naturally 
overexpresses deconjugating enzymes (i.e., β-glucuronidase), the glucuronide promoiety 
would be cleaved, leaving active curcumin at the site of action. This mechanism of 
chemoprevention by oral curcumin has multiple benefits: 1.) both curcumin and curcumin 
glucuronide are relatively nontoxic to normal, healthy cells; 2.) curcumin upon 
absorption is naturally metabolized to curcumin glucuronide; and 3.) enzymes that de-
conjugate the glucuronide to re-form active curcumin are naturally overexpressed at sites 
where the active drug is desired. 
 
1.10 β-Glucuronidase 
 Human β-glucuronidase is a 332 kDa homotetrameric glycoprotein with four 
identical subunits of 78 kDa molecular weight [103]. While β-glucuronidase is primarily 
localized in the cell lysosome, the enzyme is also found in significant quantities in the 
necrotic areas of many tumors, especially in larger tumors containing many necrotic cells 
[104]. The optimal pH for human β-glucuronidase activity is ~4, resembling the pH in 
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lysosomes. At physiological pH of 7.4, the enzyme exhibits ~10% of normal catalytic 
activity. β-glucuronidase remains stable and intact at temperatures up to 70°C [105]. 
Catalytic activity as determined by protein structural analysis is associated primarily with 
three amino acid residues in the active site: Glu540 serves as a nucleophile, Glu451 is an 
acid-base catalyst/proton donor, and Tyr504 is also important, though its role has yet to be 
determined [106]. Structurally, β-glucuronidase contains a type of β-barrel known as a 
jelly roll barrel as well as a TIM barrel, in which eight α-helices and eight parallel β-
strands alternate along the peptide backbone [107].  
To understand the role of β-glucuronidase in cancer chemoprevention, a brief 
overview of phase II drug metabolism via glucuronidation is essential. The conjugation 
of glucuronic acid to xenobiotics is a fundamental mechanism in nature for detoxifying 
and eliminating lipophilic compounds from the body [108]. Glucuronidation is a primary 
pathway of phase II metabolism, in which UDP-glucuronosyltransferase (UGT) 
conjugates glucuronic acid to a lipophilic drug molecule. Substrates for UGTs include 
phenols, alcohols, carboxylic acids, and aromatic acids. The conjugation reaction requires 
the cofactor uridine diphosphateglucuronic (UDP-glucuronic) acid and is catalyzed by 
UGTs located mainly in the endoplasmic reticulum of hepatocytes. Glucuronide 
metabolites are polar, hydrophilic, and water-soluble, causing these compounds to be 
more readily excreted from the body via renal or biliary clearance. Excretion is promoted 
by the carboxylic acid moiety of glucuronic acid, which is ionized at physiological pH 
and thus increases the aqueous solubility of the drug. As a result, the hydrophilic 
glucuronide metabolite is recognized by biliary and renal organic anion transport systems 
and is subsequently eliminated.   
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β-glucuronidase is an enzyme that hydrolyzes the glycosidic bond of glucuronides 
and is overexpressed in the necrotic regions of many human tumors [110]. Its primary 
physiological function is to catalyze the breakdown of complex carbohydrates. 
Overexpression of β-glucuronidase in the tumor microenvironment in comparison to its 
relatively minimal expression levels in normal cells holds potential in targeting 
chemotherapeutic agents specifically to the tumor site [109, 110]. A key approach that is 
developed for tumor selective prodrug conversion is prodrug monotherapy, in which the 
endogenous enzyme that is elevated in tumors is exploited for therapeutic benefit; β-
glucuronidase at the tumor site converts relatively nontoxic prodrugs into active cytotoxic 
compounds, allowing for better selectivity and efficacy for chemopreventive and 
chemotherapeutic agents. A wide range of malignancies, including breast, lung and 
gastrointestinal tract carcinomas, and melanomas have shown high levels of β-
glucuronidase localized in necrotic areas, as evidenced by enzyme immunohistochemistry 
(IHC) on tumor biopsies [111]. Previous studies have shown significant differences in 
growth inhibition effects between small non-necrotic tumors and larger tumors when 
human tumor xenograft models are treated with a glucuronide prodrug. It was observed 
then that the extent of chemopreventive efficacy was strongly associated with the 
expression of β-glucuronidase in areas of tumor necrosis [104, 112, 113]. Expression of 
β-glucuronidase is due largely to the liberation of monocytes (macrophages), 
granulocytes (neutrophils), and other factors involved in inflammatory response in the 
necrotic areas of human tumor tissue. Disintegrating tumor cells contribute minimally to 
β-glucuronidase release [114]. Previous studies have shown that an increased β-
glucuronidase expression results in the increased activity of the enzyme in tumor tissue as 
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opposed to normal tissue, where there is practically no expression. For example, studies 
have shown that, after isolated perfusion with a glucuronide prodrug of doxorubicin, 
uptake of doxorubicin into bronchial carcinoma was much greater as compared to uptake 
levels into normal lung lobes extracted from the same patients [109]. Correlating enzyme 
expression in pancreatic carcinoma homogenates with glucuronide prodrug bioactivation 
of doxorubicin also yielded similar findings [115]. These studies convey the 
chemopreventive potential of elevated β-glucuronidase levels in tumor tissue.  
 
1.11 β-Glucuronidase Hydrolysis Reaction 
 Hydrolysis is a reaction in which a chemical bond in a molecule is cleaved by the 
addition of water. The chemical process in which a water molecule is added to a 
molecular compound involves the degradation of that compound into its component 
molecules. Such a process is essential to biological systems, as in the case of breaking 
down complex carbohydrates into its component sugar molecules. Hydrolysis is often 
catalyzed by an enzyme. β-glucuronidase, an enzyme of the glycosidase family that aids 
in breakdown of complex carbohydrates, catalyzes the hydrolysis of β-D-glucuronide 
from the non-reducing end of glycosaminoglycans [116-118]. The products of the 
reaction are an alcohol and the cleaved β-D-glucuronic acid moiety (Figure 1.2). In the 
case that “R” is a drug molecule in the β-glucuronidase hydrolysis reaction, the enzyme 
substrate would be an inactive glucuronidated drug, and the product yielded would be an 
active drug molecule. For the reaction shown in Figure 1.2, β-D-glucuronide is the 
inactive glucuronidated drug, the alcohol is the active drug molecule, and the β-D-
glucuronic acid is the cleaved glucuronide moiety.  
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Figure 1.2. Hydrolysis Reaction with β-Glucuronidase. 
 
 
1.12 Curcumin Metabolism and De-Glucuronidation 
 A major metabolic pathway of curcumin upon oral administration is phase II 
metabolism, in which curcumin undergoes glucuronidation [119]. UDP-
glucuronosyltransferases (UGTs) present within the enterocytes along the gastrointestinal 
tract and hepatocytes within the liver catalyze a glucuronide transfer reaction from co-
substrate uridine 5’-diphosphoglucuronic acid (UDPGA) to a hydroxy functional group 
of curcumin [120]. This glucuronidation reaction yields curcumin glucuronide, an 
inactive molecule that is readily excreted due to its hydrophilic nature. [119]. Curcumin 
glucuronide that reaches β-glucuronidase at sites of inflammation or disease, however, 
undergoes a hydrolysis reaction in which the glucuronide moiety is cleaved from the 
inactive metabolite, thus yielding active curcumin as the product along with the 
byproduct β-D-glucuronic acid (Figure 1.3). 
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Figure 1.3. Curcumin metabolism to curcumin glucuronide by UDP-
glucuronosyltransferase, and subsequent hydrolysis of curcumin glucuronide to curcumin 
by β-glucuronidase. 
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1.13  Literature Reports of β-Glucuronidase Expression, Activity, and Prodrug 
Activation 
 Several reports point to the elevated levels of β-glucuronidase in inflammatory 
and disease pathology. β-glucuronidase expression and activity was shown to be highly 
concentrated in regions of necrosis in lung cancer surgery specimens, as determined by 
enzyme histochemistry (EHC) and TdT reaction experiments [121]. Within these necrotic 
regions, cellular debris from dead cells were seen to bear markers for the presence of 
human monocytes and/or granulocytes, and so it is most likely that these immune 
response cells liberate β-glucuronidase. Enzyme activity from disintegrating cells, 
however, was only marginal. Additionally, a strong correlation was observed between the 
regions of high local β-glucuronidase concentration and areas of abundant and rapid 
DNA degradation, as seen by immunohistochemistry of human tumor xenografts and 
TdT reaction products [121]. From these observations, it was concluded that the 
inflammatory response and immune cells that are present within the necrotic regions of 
tumors largely contribute to β-glucuronidase activity.  
 There has also been evidence for a strong correlation between the β-glucuronidase 
content or expression that is present within tissue and the levels of enzyme activity 
observed. One study looked at the β-glucuronidase contents in healthy human pancreas, 
chronic pancreatitis, and pancreatic adenocarcinoma samples and how the enzyme levels 
in the tissue homogenates measure to their respective specific activities. It was found that 
there is a direct correlation between enzyme expression levels and specific activity; 
tissues with minimal β-glucuronidase levels (i.e., normal pancreatic tissue) had the lowest 
activity, while tissues with high β-glucuronidase content (i.e., pancreatitis and pancreatic 
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adenocarcinoma tissue) had the greatest specific activities [122]. Enzyme activity was 
determined by monitoring the levels of 4-methylumbelliferyl-β-D-glucuronide (MUG) 
conversion to parent compound 4-methylumbelliferone (MU) by HPLC analysis in these 
studies. 
Several epidemiological studies have reported in vitro and in vivo β-glucuronidase 
mediated activation of both exogenously and endogenously generated prodrugs. An 
example of an exogenously generated prodrug is HMR 1826 (N-[4-β-Glucuronyl-3-
nitrobenzyloxycarbonyl]doxorubicin), a derivative of doxorubicin with a bound 
glucuronic acid moiety that exhibits a much lower systemic toxicity profile as compared 
to doxorubicin. As for an endogenously generated metabolite prodrug, SN-38-
glucuronide (SN-38G) is a prime example. SN-38G is an inactive metabolite of SN-38, a 
potent topoisomerase I inhibitor. Irinotecan (CPT-11) is a clinically important prodrug 
that is used to treat advanced colorectal and lung cancer [123]. CPT-11 is hydrolyzed by 
carboxyesterases to yield the active metabolite SN-38, which can be further metabolized 
to inactive SN-38G by various glucuronosyltransferases (UGTs). In vitro and in vivo 
studies have been performed with both HMR 1826 and CPT-11 to evaluate the 
accumulation levels and efficacy of doxorubicin and SN-38, respectively, based on the 
activation potential of β-glucuronidase. 
 When administering a prodrug for a therapeutic regimen, the main goal is to 
reduce systemic toxicity by improving the drug targeting and accumulated drug 
concentration at the site of action. Evidence of this was shown when normal lung and 
bronchial carcinoma tissue resected from human patients and tissues were perfused with 
either free drug doxorubicin or HMR 1826 [124]. Final tissue concentrations of 
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doxorubicin in normal lung and tumor were determined after 2.5 hours of perfusion with 
either 5 µg/mL doxorubicin or 400 µg/mL HMR 1826 by HPLC. While doxorubicin 
levels were not significantly different between the form of drug administered in normal 
lung tissue – most likely due to marginal β-glucuronidase activity – the concentrations of 
doxorubicin were markedly different in tumor. Tumor tissue perfused with HMR 1826 
had a mean doxorubicin concentration of 14.04 ± 12.9 ug/g, while perfusion with free 
doxorubicin gave a final mean doxorubicin concentration of 1.78 ± 3.11 ug/g [124]. The 
increased concentration of active drug in the tumor when administered in the prodrug 
form shows the potential of activation selectivity based on the action of β-glucuronidase. 
 β-glucuronidase activity is just as important in activating endogenously generated 
prodrugs. It has been shown that significant levels of active SN-38 are formed from SN-
38G in both liver and human neuroblastoma NB1691 xenograft tumor tissue collected 
from female SCID mice [123]. Mice were dosed intravenously with CPT-11 at 10 mg/kg, 
and following activation to SN-38 and successive metabolism to SN-38G, β-
glucuronidase activity was determined by monitoring the rate of SN-38G to SN-38 
conversion. Not only was there significant β-glucuronidase activity found in both liver 
and tumor homogenates, but it was also observed that the β-glucuronidase activity was 
not saturable over the SN-38G concentration range of 0.12 – 50 µM, as determined by the 
linearity of the SN-38G concentration versus SN-38 production profiles for both tumor 
and liver homogenates.  
 In another set of studies that correlate in vitro cell cytotoxicity experiments with 
in vivo efficacy in animal xenografts, the importance of prodrug activation by β-
glucuronidase is reiterated. Studies were performed with parent EJ human bladder 
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carcinoma cells (EJ) and EJ cells expressing membrane-tethered β-glucuronidase 
(EJ/mβG) implanted in female SCID mice [125]. β-glucuronidase activity assays showed 
significant activity in incubation with both cultured EJ/mβG cells and EJ/mβG tumor 
homogenates, whereas minimal activity was seen with parent EJ cells and EJ tumor 
homogenates. In subsequent in vivo efficacy studies with human xenografts of both EJ 
and EJ/mβG tumors, the EJ/mβG tumor-bearing mice group receiving two daily 
intravenous doses of CPT-11 at 10 mg/kg showed the treatment to be most efficacious, as 
compared to other groups that were either EJ tumor-bearing receiving CPT-11 treatments 
or EJ/mβG tumor-bearing receiving PBS control treatments [125]. Efficacy was 
determined based on average tumor volumes at the end of the treatment study, with the 
EJ/mβG tumor-bearing mice receiving CPT-11 treatment having the lowest tumor 
volumes after 14 days of daily treatment. These studies further show that β-glucuronidase 
play an essential role in activating glucuronidated prodrugs. 
 β-glucuronidase not only exhibits higher specific activity with its increased levels 
in inflammatory and disease tissue, but enzyme kinetics studies also show that the rate of 
conversion is fastest in tissue having the highest β-glucuronidase content. In one study, 2 
substrates of β-glucuronidase – MUG and HMR 1826 – were used to study the enzyme 
kinetics with the 3 types of pancreatic tissue as mentioned above [122]. With increasing 
serial two-fold concentrations of either drug (MUG: 0.56 – 5 mM; HMR 1826: 6.25 – 
400 µM) in incubation with tissue homogenates (2.25 µg total protein/50 uL, 30 minutes, 
37°C for MUG; 1.13 µg total protein/50 µL, 2 hours, 37°C for HMR 1826), the 
increasing conversion to parent compound or active drug occurred by either a sigmoidal 
velocity curve or Michaelis-Menten-like kinetics. Vmax for prodrug activation was highest 
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in pancreatic cancer tissue homogenate as compared to pancreatitis and healthy tissue for 
both drugs, indicating that the Vmax values vary depending on the tissue type and their 
associated enzyme contents [122]. 
 Activity levels of β-glucuronidase are dependent on reaction pH conditions as 
well as on temperature. In studies with human lung cancer and healthy lung tissue 
homogenate involving HMR 1826, it has been documented that enzymatic activity is 
about 15 times higher at pH 5.0 (1582 ± 190.2 nmol doxorubicin formed/hour/mg 
protein) than at physiological pH of 7.4 (100.0 ± 2.6 nmol doxorubicin/hour/mg protein). 
A nearly 5-fold increase in β-glucuronidase activity was seen at reaction pH 6.5, the pH 
of tumor tissue (466.8 ± 98.1 nmol doxorubicin/hour/mg protein) as compared to reaction 
at pH 7.5, which corresponds to extracellular tissue in healthy lung tissue (100.0 ± 2.6 
nmol doxorubicin/hour/mg protein). Enzyme kinetic studies show Vmax of β-
glucuronidase activity to be an estimated 2-3 times greater in a reaction environment of 
pH 6.5 than at pH 7.5 [126].  
 Additionally, further studies show that temperature and pH conditions are factors 
that affect β-glucuronidase activity and the degree of enzymatic cleavage as well. The 
function of β-glucuronidase in pancreatic tissue of varying disease stages has been 
assessed based on reaction temperature at physiological pH [122].  Temperatures of 37°C 
(physiological) and 42°C (hyperthermia treatment) were used in the study. Their 
experiment results showed that increased β-glucuronidase cleavage of both MUG and 
HMR 1826 occurred at elevated temperatures (42°C) as compared to normal 
physiological temperatures. Enhanced release of parent compound MU and doxorubicin 
was observed at 42°C, and a linear correlation between temperature and levels of β-
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glucuronidase activity and therefore parent drug released was even observed from 37°C 
to 57°C. Thus, hyperthermia treatment may be beneficial in terms of increased enzyme 
activity to enhance drug targeting and accumulation levels at the site of action. Overall, it 
can be concluded from these studies that temperature and pH conditions of the β-
glucuronidase hydrolysis reaction has a significant effect on the activation of prodrugs, 
and that the acidic tumor microenvironment in the extracellular matrix plays a role in 
increasing the activity of β-glucuronidase. 
 Considering the correlation between β-glucuronidase expression with specific 
activity and the effect of pH conditions on enzyme activity, glucuronidated prodrugs are 
not only activated at greater enzyme levels due to increased β-glucuronidase expression, 
but the acidic microenvironment within the extracellular matrix of the tumor also serves 
to promote increased activity. In healthy normal tissue, marginal levels of β-
glucuronidase plus physiological pH conditions yield minimal levels of enzymatic 
activity. In inflammatory and tumor tissue, however, increased levels of β-glucuronidase 
coupled with a lower pH in the tumor microenvironment work in tandem to increase 
specific activity levels. 
 Prodrug activation by β-glucuronidase alone is not only an effective means of 
prodrug delivery in itself, but there has also been evidence of glucuronide prodrug 
antitumor activity synergizing with targeting the tumor microenvironment for anti-
angiogenesis. One study reported the use of a novel cell-impermeable, inactive 
glucuronide prodrug 9-aminocamptothecin glucuronide (9ACG) with antiangiogenic 
monoclonal antibody DC101 having a synergistic effect in limiting tumor cell growth and 
xenograft tumor growth [127]. These studies also showed the importance that immunity 
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plays in potentiating such synergy – treatments of 9ACG resulted in potent antitumor 
activity in human tumor xenografts of colon adenocarcinoma LS174T cells in Balb/c 
nu/nu nude mice immunodeficient in T-cells, whereas the same treatments in NOD/SCID 
mice deficient in immune cells such as macrophages and neutrophils bearing the same 
xenografted tumors showed minimal antitumor response. This is again suggestive of 
these immune cells playing a crucial role in liberating and activating β-glucuronidase in 
the extracellular matrix. When antiangiogenic DC101 was simultaneously administered 
with 9ACG, antitumor activity was further enhanced and survival of mice bearing 
resistant human tumor xenografts was prolonged, most likely due to the increased 
neutrophil infiltration and tumor vessel normalization that is associated with DC101 
administration. These results show that not only is β-glucuronidase a key player in 
prodrug activation, but the activity can be further enhanced with the co-administration of 
other drugs that may alter the tumor microenvironment to induce greater immune cell 
infiltration.  
 
1.14 Self-Microemulsifying Drug Delivery System (SMEDDS) 
 Oral drug administration is the primary route of administration for approximately 
85% of all drugs sold in the United States and Europe [128]. Drugs can be divided into 
four classes according to the Biopharmaceutical Classification System (BCS) based on 
drug solubility and permeability: 
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Class I: High Permeability and High Solubility 
Class II: High Permeability and Low Solubility  
Class III: Low Permeability and High Solubility 
Class IV: Low Permeability and Low Solubility 
 
Curcumin is classified as a class IV drug that exhibits both low solubility and low 
permeability. Low solubility causes poor drug dissolution and low permeability leads to 
poor absorption through the gut wall. These factors, combined with the extensive first-
pass metabolism of curcumin, contribute to its low systemic bioavailability.  
 Self-microemulsifying drug delivery systems (SMEDDS) have been utilized in 
previous studies to improve the oral bioavailability of hydrophobic compounds that have 
low solubility. SMEDDS typically consist of optically isotropic (i.e., has only one 
refractive index) mixtures of oil, surfactant, and co-surfactant that upon addition to 
aqueous media, form stable oil-in-water microemulsions. Microemulsions are transparent 
or translucent, isotropic colloidal dispersions that have low viscosity and are 
thermodynamically stable. SMEDDS present solubilized drugs in stable oil-in-water 
nanoemulsions of small droplet sizes (< 50 nm), which can be formed either by adding 
SMEDDS to an aqueous phase prior to dosing or with aqueous GI fluids upon 
administration [129]. Microemulsions improve the drug absorption by essentially 
improving drug dissolution [130-131]. 
 Depending on the composition ratios of aqueous phase, surfactant, co-surfactant, 
and oil, a microemulsion can exist as one of three types: (1) water-in-oil (w/o) system, 
which consists of an aqueous phase dispersed in a continuous oil phase; (2) oil-in-water 
(o/w), where oil is the dispersed phase and water is the continuous phase; and (3) an oil 
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and water bi-continuous microemulsion in which the amount of oil and water present are 
equivalent [132]. Differences between microemulsions and emulsions are that while 
microemulsions form droplet sizes of less than 50 nm, are translucent, and form 
spontaneously, emulsions have larger droplet sizes (>200 nm), are opaque and turbid in 
appearance, and require external energy input to formulate. The translucency of a 
microemulsion is due to light being able to penetrate through without being scattered 
because of the smaller dispersed phase droplet sizes. Two major advantages of using 
microemulsions over emulsions in improving drug dissolution rate are that 
microemulsions are thermodynamically stable once formed and that an external force is 
not required for formation.   
 Microemulsion systems for pharmaceutical purposes are composed of surfactants, 
co-surfactants, and lipids that are generally regarded as safe (GRAS) by the FDA. Oils 
and lipids serve primarily to dissolve the drug and enhance drug absorption in the GI 
tract. Surfactants lower the interfacial tension between the two immiscible oil and 
aqueous phases, while co-surfactants are weaker surfactants that enhance the ability of 
the surfactant to further decrease surface tension. Lipids that are widely used in 
microemulsions include both natural oils, such as triglycerides (vegetable oils – palm, 
peanut, corn, olive), and synthetic oils, including ethyl oleate, isopropyl palmitate, 
Captex® 300, and Captex® 355 [133]. Commonly used surfactants are zwitterionic and 
nonionic, including hydrogenated castor oils and sucrose esters [134]. For co-surfactants, 
ethanol and mono- and di-glycerides are the most commonly employed in microemulsion 
formulations [135-136]. 
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 Examples of the clinical application of SMEDDS to improve drug bioavailability 
and commercially available microemulsions include ritonavir (Norvir®), saquinavir 
(Fortovase®), and cyclosporine (Sandimmune® and Sandimmune Neoral®). Cyclosporin 
A (CsA), a potent immunosuppressant widely used in organ transplantation to prevent 
rejection, is a prime example of a successful marketed drug microemulsion formulation 
to enhance bioavailability. Cyclosporine is highly lipophilic and has very poor solubility, 
and therefore has low bioavailability when orally administered. Patient-to-patient oral 
bioavailability was also highly variable because of such properties. Development of 
cyclosporine in a microemulsion formulation has shown positive results in dose 
proportion pharmacokinetic studies in greatly improving bioavailability and lowering 
inter-patient variability [137]. Despite such success with Cyclosporin A, however, large-
scale commercialization of using the microemulsion formulation approach to enhance the 
oral bioavailability of lipophilic, low soluble drugs proves to be difficult. This is due to 
variability in the improvement of oral bioavailability from drug to drug, potential 
precipitation of the hydrophilic drug in a continuous aqeuous phase, and surfactant and 
co-surfactant use limitations.  
 Due to previous reports of success in microemulsions enhancing the 
bioavailability of low dissolution drugs, we chose this approach to increase drug 
absorption and therefore systemic bioavailability of curcumin. Studies in this thesis 
examining curcumin accumulation and efficacy, as well as parent drug and metabolite 
pharmacokinetics, utilized a curcumin SMEDDS formulation for oral administration.  
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1.15 Clinical Overview of Breast Cancer 
The preventive and therapeutic effects of curcumin are wide ranging on a great 
number of inflammatory diseases including cancer; however, the focus of this thesis is to 
investigate the chemopreventive potential of curcumin against breast cancer. Breast 
cancer is the most common cancer among American women besides lung cancer, and in 
2015, it is estimated that approximately 30% of new cancer diagnoses in women will be 
breast cancers – 231,840 new cases being invasive, and 60,290 new cases being non-
invasive (in situ carcinoma). About 1 in 8 women (~12%) will develop invasive breast 
cancer in her lifetime, and as of this year, more than 2.8 million women in the U.S. have 
a history of breast cancer, which includes women who are either currently undergoing or 
have finished treatment [138-139]. Caucasian women are at a slightly higher risk for 
breast cancer than African-American women, though in women under 45, the disease is 
more prevalent in African-American women than Caucasian women. Overall statistics 
show African-American women having a higher mortality rate from breast cancer than 
any other ethnicity. Death rates have been decreasing since 1989 due most likely to 
advances in treatment, earlier detection, and increased awareness. Less than 15% of 
women diagnosed with breast cancer have a family member who has also had breast 
cancer, though a woman’s risk of breast cancer doubles if an immediate relative such as a 
mother, sister, or daughter had been diagnosed [140].  
The disease is caused by genetic mutations that are a result of environmental 
factors and lifestyle such as diet, exercise, and stress levels, rather than by inherited 
genetic predisposition – 85% of breast cancer patients have no family history of breast 
cancer. The exception, however, is the 5-10% of breast cancer cases that are linked to 
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inherited gene mutation, such as mutations of the BRCA1 and BRCA2 genes, which 
increases the lifetime risk of developing breast cancer to 45-65%. Ovarian cancer risk is 
also increased with mutations in these genes [141, 142]. Prognosis and treatment options 
are largely dependent on breast cancer type and stage at the time of diagnosis. In general, 
the 5-year relative survival rate is >90% when the disease is diagnosed in the initial 
stages (0 or I), but drops significantly when it is diagnosed in the more advanced 
invasive/metastatic stages (III and IV), which has a much lower survival rate at 5-years 
post-diagnosis (<20%) [143-145].  
 Breast cancer is the uncontrolled growth of breast epithelial cells, often referring 
to a malignant tumor that has formed from cells of the breast. A tumor can be either 
benign, which is non-invasive and therefore considered non-cancerous, or malignant, 
which is the invasive form that poses the danger of spreading to other parts of the body. 
Breast cancer most commonly originates in either the lobules, which are the milk-
producing glands, or the ducts, the channels that carry milk from the lobules to the nipple. 
It is less common for breast cancer to begin in stromal tissue, which are the fatty and 
fibrous connective tissues that provide structure, support, and protection. Typical human 
mammary glands comprise of approximately 20 milk-secreting lobules, which are made 
up of milk-producing epithelial cells and myoepithelial cells. Development and function 
of the lobules and ducts is highly dependent on the hormonal levels of estrogen and 
progesterone [146]. As time passes, cancer cells have the potential to breach the 
basement membrane that is containing them in situ, intravasate into systemic circulation, 
and invade nearby healthy breast tissue or lymph nodes, which are small organs that 
serve to filter out foreign substances. Once in the lymph nodes, cancer cells can follow 
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circulation to other parts of the body, where extravasation and colonization at distant 
metastatic sites can occur [147].  
The stage of breast cancer is a reference to the degree of how far the cancer cells 
have advanced beyond the primary tumor. Four characteristics determine cancer stage: 
cancer size, whether the cancer is invasive or non-invasive, whether cancer is present in 
the lymph nodes, and whether metastasis has occurred. Breast cancer stage can also be 
described as local (stages 0, I – cancer is confined within the breast), regional (stages I, 
II, III – lymph nodes are involved), or distant (stages III, IV – cancer has spread to other 
parts of the body) [148]. The following are the stages of breast cancer: 
 
Stage 0: The cancer has been diagnosed early enough where it is still in its initial 
stages of developing in the breast ducts and has remained there – often 
termed in situ.  
Stage I:  Breast cancer cells start to become invasive, penetrating into either healthy 
fatty breast tissue or the lymph nodes.  
Stage II: The cancer has either grown, spread, or both. Tumor size remains small, if 
there is one at all. There may be no cancer in the lymph nodes, or it may 
have spread to as many as three glands.  
Stage III: Breast cancer is considered advanced at this point, but was diagnosed 
before it spread to bones and distant organs.  
Stage IV: Cancer cells have metastasized to distant sites in the body, with the most 
common being in bones, lungs, liver, and brain.  
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Another important aspect of breast cancer that is highly considered in prognosis 
and treatment options is molecular subtype [149, 150]. While cancer subtype is now a 
major determinant of the appropriate therapeutic regimens in the clinic, breast cancer 
research in recent years have also actively focused on developing new therapies based on 
molecular subtype. The disease is divided into four major subtypes: luminal A, luminal 
B, triple negative/basal-like, and HER-2+ (Table 1.1). 
 
Table 1.1: Breast Cancer Subtypes and Prevalence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 [151-­156]	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Prognosis and decisions for treatment options are primarily based on tumor stage 
and cancer subtype – that is, based on hormone (estrogen/progesterone) receptor status 
and HER-2/neu status. Tumors overexpressing estrogen and progesterone receptors (ER+ 
and PR+, respectively) are most often treated with hormone-based therapies [157]. 
Examples include Tamoxifen, Toremifene (Fareston®), and Fulvestrant (Faslodex®), 
which all act to block estrogen from binding to estrogen receptors in breast cancer cells 
and thereby inhibit cell growth and division [158]. HER-2+ type tumors, or tumors that 
are of cells overexpressing the human epidermal growth factor receptor 2 on their 
surface, are often treated with tyrosine kinase inhibitors (TKIs) along with other 
chemotherapeutic agents such as docetaxel, doxorubicin, cyclophosphamide, carboplatin, 
and paclitaxel [159, 160]. Trastuzumab (Herceptin®) is a monoclonal antibody that is 
widely used for treatment of HER-2+ breast cancer. Triple negative subtype, so called 
because it overexpresses neither hormone receptors nor HER-2 receptor, is rather difficult 
to treat, but has nonetheless proven to be responsive to radiation and chemotherapeutic 
treatments. Other less common subtypes include normal breast-like, apocrine molecular 
type, and claudin-low type. Breast cancers that do not fall into any of the above-listed 
subtype categories are often termed unclassified.  
 
1.16 Models for Studying Breast Cancer In Vivo 
Breast cancer is not one single disease, but rather a multitude of breast diseases 
that have diverse histopathological features, genetic variations, and a wide range of 
prognostic outcomes [161]. Due to the complexity of this heterogeneic disease, our 
knowledge of breast cancer biology and its effective treatment is limited by the 
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availability of experimental model systems that mimic the typical stages of tumor 
development in humans. Despite this challenge, significant advances in knowledge have 
been made with xenograft and transgenic models. Both orthotopic xenograft and 
genetically engineered mouse (GEM) models have their strengths and limitations in 
contributing to the better understanding of breast cancer. Orthotopic human tumor 
xenografts best predict drug effects and response in human tumors, while transgenic 
models are best used for investigating the role of specific genes in tumorigenesis in an 
immunocompetent environment. 
 
1.16.1 Xenograft Models 
 Human tumor xenograft models have been widely employed to investigate the 
malignant transformation of tumorigenesis – invasion and metastasis – and response to 
therapy based on specific tumor type [162]. In xenograft models, human tumor cells are 
transplanted directly either under the skin (subcutaneous) or into the type of organ of 
tumor origin (orthotopic) in immunocompromised mice. Xenografts of cells from one 
species into a different species (i.e., human cells into a mouse) require the host species to 
be immunocompromised so as to not reject the cells from another species.  
Immunocomprised mice that are used in xenografts include athymic nude mice 
and severely compromised immunodeficient (SCID) mice, as well as other types of 
immunocompromised mice, such as nonobese diabetic/severely compromised 
immunodeficient (NOD/SCID) mice. Athymic nude mice lack a thymus and therefore are 
unable to produce T cells. In animals homozygous for the SCID mutation, T and B cell 
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lymphocyte development is impaired, and in NOD/SCID mice, natural killer (NK) cell 
function is deficient in addition to lacking T and B cells [163].  
Direct injection of breast cancer cells into the mammary glands of mice is termed 
as an orthotopic xenograft. Cells can also be injected intravenously by tail vein injection 
to study the effects of cell colonization and treatment at common metastasis sites, such as 
the lungs, brain, liver, lymph nodes, and bones. Studies that investigate the treatment 
effects on primary tumor would benefit most from subcutaneous or orthotopic xenografts; 
for metastatic studies involving characterization of circulating tumor cells and treatment 
of metastatic tumors, intravenous injection of cells would be the preferred route of 
inoculation due to the direct administration of cells into the systemic circulation. 
A wide array of breast cancer cell lines is available for both in vitro and in vivo 
studies. These cell lines range greatly in terms of genetic profile, and are representative of 
the heterogeneity of human patient tumors [164, 165]. Cell lines are characterized based 
on their syngeneity to type of species (i.e., mouse or human), cell type (i.e., epithelial), 
tissue (i.e., mammary or breast), morphology (i.e., epithelial), and sub-type (i.e., ER/PR+, 
HER-2 overexpressed, or triple negative in the case of breast cancer). Selecting cell lines 
for their specific properties and phenotypes is important in understanding the 
functionalities and treatment responses to that specific group or subtype of disease.  
 A major disadvantage to xenograft models is that mice are immunocompromised 
and therefore the tumor microenvironment is not a true representation of patient tumors, 
where the immune system plays a crucial role in tumorigenesis. Tumor cells are already 
tumorigenic prior to injection, and so the initiation stages and treatment options at these 
stages cannot be examined. Furthermore, there are genetic differences between the cells 
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cultured in vitro for xenograft as compared to cells that are of the primary tumor in the 
clinic, and so results from treating xenografted tumors may be different than the results of 
that same treatment in the clinic [161].  
Direct transplantation of primary human tumor cells into immunocomprimised 
mice (patient-derived xenografts; PDX), however, offers several advantages. Direct 
orthotopic xenografts can predict response of the tumor cells to specific drugs in a human 
patient, as well as provide a realistic representation of the complex heterogeneity of 
tumor cells in the mouse model. Moreover, these models can rapidly predict a human 
tumor response to a given therapeutic regime based on the observed results. 
 
1.16.2 Transgenic Models 
Transgenic models are widely employed for studying human diseases and their 
treatments. GEM contribute extensively to understanding the genes involved in the 
promotion and progression of breast cancer. Transgenic models are produced by either 
overexpressing an oncogene or suppressing a tumor suppressor gene, allowing for the 
study of specific treatments for certain genotypes [161]. One key advantage of such 
models is that treatments can be studied from the initiation stage of tumorigenesis, unlike 
in xenograft models. Gene expression specific to the mammary tissue can be generated 
using mouse mammary tumor virus long terminal repeat (MMTV-LTR) and whey acidic 
protein (WAP) promoters [166]. Oncogenes such as Erbb2, Myc, Ccnd1 (encoding cyclin 
D1), polyoma virus middle T (PyMT), and Hras, and tumor suppressor genes such as 
Trp53, Brca1, and Pten (phosphatase and tensin homologue) have been modified to 
create various transgenic models specific to breast cancer [166-169].  
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 There are several advantages and disadvantages to using transgenic models for 
studying the treatment effects of breast cancer. The advantages of working with GEM 
include: (1) many genetic backgrounds and specific abnormalities can be analyzed by 
using several strains of mice; (2) tumorigenesis can be monitored from the initial stages 
of development and so a variety of therapeutic approaches can be studied at each stage; 
(3) mutations closely relate to those found in human tumors; and (4) the tumor is present 
in an immunocompetent environment, which mimics a realistic tumor microenvironment. 
Disadvantages to these models are: (1) only a limited number of genes are targeted in 
GEM and so the complex heterogeneity of human tumors cells and the microenvironment 
is not mirrored; (2) development of such models are expensive and the time required for 
experimental work is much longer; (3) tumor development is highly variable; and (4) 
since GEM are still mouse tumors, it is difficult to predict the outcomes of a similar 
treatment on human tumors, and so the translation of response from mouse to the clinic 
may be limited [170].  
 
1.16.2.1 Balb-neuT 
 To incorporate a more realistic mouse model that closely mimics what occurs 
clinically with HER-2+ breast cancer, the Balb-neuT transgenic mouse model was 
employed for both in vitro and in vivo studies in this thesis. The Balb-neuT model is a 
genetically engineered mouse model that overexpresses an activated form of the rat HER-
2/neu oncogene driven under the transcriptional control of the mouse mammary tumor 
virus (MMTV) promoter/enhancer. The mutated gene encodes a single point mutation at 
position 664 in the transmembrane domain of p185/neu in which a valine residue is 
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replaced with glutamic acid. This point mutation promotes both the homo- and 
heterodimerization of p185/neu and transforms the HER-2/neu proto-oncogene into a 
dominant transforming oncogene. Early onset of HER-2/neu transgene expression in the 
mammary epithelium of female Balb/c mice was associated with development of tumors 
in the entire mammary epithelium. Both the developmental stages of tumorigenesis and 
tumor histology of the model closely resemble that found in HER-2+ breast cancer in 
human patients.  
 In the Balb-neuT model, autochthonous mammary tumors that originate in the 
lobules of the mammary gland begin forming from a single cell and develop over several 
months. At 3-4 weeks of age, female Balb-neuT mice exhibit hyperplasia in the terminal 
lobular buds. Microvessels then increase in both number and density at age 4-6 weeks 
due to correspondingly higher levels of pro-angiogenic factors such as VEGF and FGF 
[171]. By 8-12 weeks, in situ carcinoma is established and by 16 weeks of age, the 
disease progresses to invasive lobular carcinoma in which the tumor is no longer locally 
confined, and can potentially metastasize to other regions of the body. At least one 
palpable tumor can be detected by 16-20 weeks; by 28 weeks, all ten mammary glands 
have palpable tumors.  
In addition to tumorigenesis being primarily driven by the overexpression of 
HER-2/neu oncogene, inflammation also plays a major role in this model. Pro-
inflammatory cytokines such as TNF-α and interleukins (i.e., IL-1β) were found to be 
increasingly overexpressed in Balb-neuT mice that were advancing from in situ 
carcinoma to invasive lobular carcinoma (12-16 weeks of age). These cytokines are 
important in activating the NF-κB pathway, in which activated NF-κB regulates gene 
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expression within the nucleus to promote inflammation [172]. Vasculature and 
microvessel growth factors within the tumor microenvironment of female Balb-neuT 
mice also decrease at the invasive lobular carcinoma stage (16 weeks) as compared to 
those in the initial hyperplastic stage of tumorigenesis. This is indicative of angiogenesis 
being most important in the onset of tumor development, and that the formation of new 
blood vessels decreases at later stages of the disease.   
 
1.17 Innovation 
The tumor-specific enzymatic activation hypothesis is highly innovative, because 
it explains, for the first time, how relatively non-toxic, dietary molecules can help reduce 
the occurrence of cancer despite their poor oral bioavailability. This hypothesis also 
points to an attractive strategy to target chemopreventive agents specifically to the tumor 
site following oral administration. That is, approaches that can improve plasma 
concentrations of the glucuronide metabolite will allow for tumor-targeted delivery of the 
active parent compound. A number of clinical trials have been conducted with very high 
oral doses of curcumin (up to 12 g/dose) [67]. Such trials have generally been considered 
as failures because these high doses failed to achieve effective plasma concentrations of 
curcumin [173]. The prodrug hypothesis would suggest that these studies should evaluate 
plasma concentration of curcumin glucuronide as an indicator of efficacy rather than that 
of curcumin.  
Because many other natural chemopreventive agents undergo glucuronidation [6], 
the research presented in this thesis here will provide a model for studies with other 
dietary agents for chemoprevention. Also, since upregulation of β-glucuronidase activity 
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is observed generally during inflammation [174], this research is expected to impact a 
wide array of inflammatory diseases.  
 
1.18 Statement of Problem and Hypothesis 
Curcumin has been shown to modulate multiple oncogenic signaling pathways 
[175]. Epidemiological studies attribute low incidence of certain types of cancers in 
specific populations to the chemopreventive and antioxidant properties of diets rich in 
curcumin [176, 177]. In general, the numerous therapeutic effects of curcumin make it a 
strong candidate for cancer chemoprevention; the polyphenol, however, has poor 
bioavailability after oral dosing [72, 87]. This raises an interesting question: how does 
dietary curcumin exhibit chemopreventive activity despite not being absorbed into the 
systemic circulation in its active form? The objective of this thesis project is to 
investigate the mechanisms behind this ‘bioavailability paradox’. 
Overexpression of β-glucuronidase and increased enzyme activity in the tumor 
tissue in comparison to its relatively minimal activity in normal cells could potentially 
explain the bioavailability paradox with curcumin and other chemopreventive agents. We 
propose that curcumin glucuronide is an inflammation-responsive natural prodrug 
that gets converted back to curcumin ‘on-demand’. In the absence of inflammation, 
curcumin would undergo extensive glucuronidation, and the inactive glucuronides will be 
excreted rapidly through renal clearance. However, in the presence of tissue 
inflammation (a common feature of many pathologies including cancer), β-glucuronidase 
is upregulated. This enables the regeneration of the active parent compound at the site of 
inflammation. Curcumin is a highly lipophilic molecule capable of tissue accumulation 
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[26]. Thus, prolonged dietary consumption of curcumin can result in a slow but 
significant accumulation of curcumin at sites of inflammation, enabling its 
chemopreventive activity. This hypothesis also explains how large oral doses of curcumin 
do not cause toxicity – water-soluble glucuronide cannot cross membrane barriers and is 
cleared rapidly from the body.  
 
1.19 Research Objectives 
The specific aims and objectives of this research project were the following: 
1. Determine the relationship between disease stage/tumor subtype and β-
glucuronidase activity in human and mouse mammary tumors 
2. Investigate the role of β-glucuronidase activity in the chemopreventive efficacy of 
oral curcumin 
3. Evaluate the pharmacokinetics of curcumin and curcumin glucuronide in wild-
type and tumor-bearing mouse models 
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Chapter II 
 
Materials and Methods 
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2.1 Materials 
Curcumin powder from Curcuma longa (Turmeric), high purity (analytical grade) 
curcumin (≥94% curcumin content), 4-Nitrophenyl β-D-glucuronide (≥98%), 4-
nitrophenol, D-saccharic acid 1,4-lactone (saccharolactone), β-glucuronidase (Helix 
pomatia), and anhydrous dimethyl sulfoxide (≥99.9%) were purchased from Sigma-
Aldrich (St. Louis, MO). Acetonitrile and methanol were purchased from Fisher 
Scientific (Pittsburgh, PA). Anti-β-glucuronidase antibody (ARP44234_T100) was 
purchased from Aviva Systems Biology (San Diego, CA). HRP-linked anti-rabbit IgG 
was purchased from Cell Signaling Technology (Beverly, MA). Anti-β-actin was 
purchased from Sigma-Aldrich. An activity-based near-infrared glucuronide trapping 
probe for imaging β-glucuronidase expression and activity in vivo was kindly provided 
by Dr. Yu-Ling Leu (Department of Pharmacy, Chia Nan University of Pharmacy and 
Science, Tainan, Taiwan). 
 
2.2 Cell Lines 
 MDA-MB-231 and MDA-MB-231 LM2 human mammary adenocarcinoma cells, 
stably transfected with luciferase, were purchased from Caliper Life Sciences. 4T1 mouse 
mammary gland tumor cells (ATCC CRL-2539), JC mouse mammary adenocarcinoma 
cells (ATCC CRL-2116), MCF-7 human mammary adenocarcinoma cells (ATCC HTB-
22), and SkBr3 human mammary adenocarcinoma cells (ATCC HTB-30) were purchased 
from the American Type Culture Collection. TuBo mouse mammary gland tumor cells, 
derived from a spontaneous mammary tumor which arose in a Balb-neuT transgenic 
mouse expressing a transforming rat neu, were kindly provided by Dr. Wei-Zen Wei 
	   54 
(Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI). MDA-
MB-231, MDA-MB-231 LM2, 4T1, and JC cells were cultured at 37°C in a humidified 
atmosphere containing 5% CO2 with RPMI 1640 (Corning Cellgro, Manassas, VA) 
supplemented with 10% FBS and 1% penicillin/streptomycin. MCF-7 cells were cultured 
with Eagle's Minimum Essential Medium (MEM) (Corning Cellgro, Manassas, VA) 
supplemented with 10% FBS and 1% penicillin/streptomycin. TuBo and SkBr3 cells 
were cultured with Dulbecco’s modified Eagle medium (DMEM) (Corning Cellgro, 
Manassas, VA) supplemented with 10% FBS and 1% penicillin/streptomycin.  
 
2.3 Animals 
In vivo studies were conducted in wild-type Balb/c, transgenic Balb-neuT, and 
athymic immunocompromised nude mice (National Cancer Institute). Balb-neuT and 
Balb/c mice were bred as described previously [178, 179]. Genotyping using tail snips 
collected at 1-3 weeks of age was performed by Transnetyx Inc. (Cordova, TN). All 
animals were 8 to 12 weeks old at the time of the experiment. All mice were maintained 
under a 12-hour light/dark cycle, given access to food and water ad libitum, and were 
maintained under a temperature-controlled environment. All studies and protocols were 
approved by the Institutional Animal Care and Use Committee of the University of 
Minnesota. 
 
2.4  Self-Microemulsifying Drug Delivery System (SMEDDS) 
The SMEDDS formulation chosen for all studies was Cremophor® EL – 
CarbitolTM – Captex® 355 (surfactant, co-surfactant, oil) at a 6:3:1 ratio. Cremophor® 
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EL and CarbitolTM were initially mixed in a 2:1 w/w, surfactant-to-cosurfactant ratio, 
followed by mixing with Captex® 355 at a 10:1 w/w, surfactant-to-oil ratio. The 
resulting formulation was the ‘Blank SMEDDS’ formulation. 30 mg of curcumin from 
Curcuma longa was solubilized in 1 gram of Blank SMEDDS to generate the ‘Curcumin 
SMEDDS’ formulation used in the oral dosing studies. 
 
2.5 β-Glucuronidase Activity Assays 
 Enzymatic activity assay in various cell lines consisted of intact, viable cells and 
cell lysates that were prepared by the freeze-thaw method, with freezing being at -80°C 
for 1 hour. Intact MDA-MB-231 cells were cultured in hypoxic conditions (< 5% O2) for 
96 hours prior to the assay. For orthotopic tumor models, tumor cells were injected into 
mammary fat pad #4 and tumors were allowed to grow to 100, 400, 700 and 1200 mm3 in 
separate cohorts of mice. When the desired volume was reached, mice were euthanized 
and the tumor tissues were collected and processed for β-glucuronidase assay. In female 
wild-type Balb/c and transgenic Balb-neuT mice, mammary tissue and spontaneously 
forming tumors were collected at 3 weeks (normal), 6 weeks (atypical mammary 
hyperplasia), 10 weeks (carcinoma in situ), 16 weeks (invasive lobular carcinoma), and 
23 weeks (metastases) of age, with each age group representing the various stages of 
tumorigenesis. All tissues were stored at -80°C. Tumors were homogenized in distilled 
water using a handheld tissue homogenizer (Omni International, Kennesaw, GA). To 
measure enzymatic activity, the conversion rate of 4-Nitrophenyl β-D-glucuronide (NPG) 
to 4-Nitrophenol (NP) was monitored (Figure 2.1). Intact cells and cell lysates were 
incubated with NPG for 2 hours at 37°C, and intact MDA-MB-231 cells subjected to 
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hypoxia were incubated with NPG for 1 and 3 hours at 37°C. Tumor homogenates with 
an initial NPG concentration of 20 µg/mL were incubated in a water bath at 37°C and 
samples were collected at 0, 1, 2, 3, and 4 hours. Ice cold acetonitrile (4:1 v/v) was added 
to the samples to stop enzymatic activity at each time point. Samples were centrifuged for 
8 minutes at 14,000 rpm, and NPG and NP concentrations in the supernatant were 
determined by HPLC.  
 
 
 
 
Figure 2.1. 4-Nitrophenyl β-D-Glucuronide (NPG) Conversion to 4-Nitrophenol (NP) 
by β-Glucuronidase. 
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2.6 In Vivo Chemopreventive Efficacy of Curcumin Formulations  
 Female virgin Balb/c nu/nu and athymic nude mice (National Cancer Institute) 
were used in these studies. Mice were randomized into three groups of six animals each. 
In the first group, mice were orally dosed (100 µL) with 100 mg/kg of curcumin 
SMEDDS formulation. The second group of mice was dosed with 100 µL of blank 
SMEDDS formulation, and the third group of mice remained untreated. Oral gavage 
treatments began one day prior to injection of tumor cells. Tumor cells were suspended in 
cell growth medium (106 cells/0.1 mL/mouse) and injected into the fourth mammary fat 
pad of the mice. Tumor size was measured using Vernier calipers and mice were weighed 
on alternate days throughout the study. Volume was calculated using the formula V = (L 
x W2)/2, where length (L) and width (W) of the tumor are the longest and shortest 
diameters, respectively. Mice were euthanized at the end of the study, and a portion of the 
tumor tissue collected was fixed with 10% phosphate-buffered formalin for histology 
while the other portion was frozen at −80°C. Formalin-fixed tissues were switched to 
70% ethanol after 24 hours. 
 
2.7 Curcumin and Curcumin Glucuronide Pharmacokinetics in Tumor-Bearing 
and Wild-Type Mice 
The pharmacokinetics of curcumin and curcumin glucuronide was evaluated in 
Balb/c mice bearing 4T1 or TuBo tumor, following either oral dosing of curcumin 
SMEDDS or intravenous (tail vein) injection of curcumin glucuronide. 4T1 and TuBo 
models were selected for their high and low specific activity levels of β-glucuronidase, 
respectively (see data section). For the oral dosing study, mice were randomized into two 
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groups of fifteen animals each. The first group of mice was injected with 4T1 tumor cells 
(106 cells/0.1 mL/mouse) suspended in cell growth medium into the fourth mammary fat 
pad. The second group received TuBo tumor cell injections in the same manner. Tumors 
were grown to a volume of 400 mm3 in size, at which mice were administered a single 
oral dose of curcumin SMEDDS (100 mg/kg curcumin). Animals were euthanized at 0.5, 
1, 2, 4, and 8 hours (n = 3 per time point) post oral administration, and plasma, tumor, 
lung, liver, and kidneys were collected.  
For intravenous dosing of curcumin glucuronide, mice were randomized into two 
groups of twenty-one mice. Mice were injected with 4T1 tumor cells in one group and 
TuBo cells in the other group as described above. Tumors were grown to a volume of 400 
mm3 in size, at which mice were administered a single intravenous dose of curcumin 
glucuronide (2 mg/kg) by tail vein injection. Animals were euthanized at 0.25, 0.5, 1, 2, 
4, 8, and 24 hours (n = 3-5 per time point per group) post intravenous administration, and 
plasma, tumor, lung, liver, and kidneys were collected. All plasma and tissues were 
stored at -80°C until further processing. 
For curcumin and curcumin glucuronide analysis, tissue samples were 
homogenized in 2 mL of distilled water using a handheld homogenizer (Omni 
International, Kennesaw, GA) and then lyophilized for 48 hours (Labconco, Kansas City, 
MO). Curcumin and curcumin glucuronide were extracted from dried tissues with 2 mL 
methanol for ~18 hours at room temperature on a rotary extractor. Acetonitrile was added 
to thawed plasma (1:4 v/v, plasma to acetonitrile) without prior processing. Tissues 
samples were centrifuged at 4,000 rpm for 10 minutes, and tissue supernatant and plasma 
samples were dried under nitrogen stream. Curcumin and curcumin glucuronide were 
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reconstituted with 0.3 mL acetonitrile. Samples were centrifuged at 14,000 rpm for 8 
minutes to rid samples of tissue debris, and final supernatant was analyzed by LC-
MS/MS to determine drug concentrations. 
Curcumin and curcumin glucuronide pharmacokinetics was also evaluated in 
wild-type Balb/c mice following curcumin glucuronide tail vein intravenous injection. 
Our aim in using wild-type Balb/c mice was to investigate curcumin and curcumin 
glucuronide levels in lung and liver tissue in a non-tumor bearing mouse model. Mice 
were administered a single intravenous dose of curcumin glucuronide by tail vein 
injection at 2 mg/kg. Animals were euthanized at 0.25, 0.5, 1, 2, 4, 8, and 24 hours (n = 
3-4 per time point) post intravenous administration, and plasma, mammary gland, lung, 
and liver were collected. All plasma and tissue were stored at -80°C until processing. 
Curcumin and curcumin glucuronide concentrations were analyzed by LC-MS/MS. 
Stability of curcumin and curcumin glucuronide during the extraction and the 
efficiency of extraction were determined by spiking tissues and plasma from untreated 
animals with 2 µg of each compound dissolved in DMSO prior to lyophilizing, followed 
by extraction and analysis of curcumin and curcumin glucuronide as described above. 
Extraction efficiency was calculated as a percent of curcumin and curcumin glucuronide 
recovered from the spiked tissues. Calculated extraction efficiencies in plasma, mammary 
tumor, lung and liver are displayed in Tables 2.1 and 2.2. 
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Table 2.1. Extraction Efficiencies of Curcumin from Plasma, Tumor, Lung, and 
Liver. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2. Extraction Efficiencies of Curcumin Glucuronide from Plasma, Tumor, 
Lung, and Liver. 
 
 
 
 
 
 
 
 
 
	   61 
2.8 Curcumin Accumulation in Transgenic and Orthotopic Models 
 Mammary tumors from female virgin transgenic Balb-neuT mice and Balb/c mice 
bearing orthotopic JC, TuBo, 4T1 or no tumors were used to evaluate the accumulation of 
curcumin in tumor. JC and TuBo tumors were collected from the month-long oral dosing 
efficacy studies and used for these studies. The 4T1 model was selected for its high 
specific activity levels of β-glucuronidase (see data section). The first group of mice was 
injected with 4T1 tumor cells (106 cells/0.1 mL/mouse) suspended in cell growth medium 
into the fourth mammary fat pad. The second group did not receive cell injections and 
served as the control group (n = 5-6 per group). Both groups of mice were dosed with 
oral curcumin SMEDDS (100 µL) at 100 mg/kg once the tumor-bearing mice reached 
tumor volumes of 400 mm3. Daily oral dosing of the curcumin SMEDDS formulation 
was administered for 14 consecutive days. On the last day of the study, mice were 
euthanized at 1 hour post-dose, plasma and tumors were collected and stored at -80°C 
until further processing. To extract drug from plasma, acetonitrile was first added to 
thawed plasma (1:4 v/v, plasma to acetonitrile) to precipitate proteins. Plasma samples 
were centrifuged at 14,000 rpm for 8 minutes, and the supernatant was used directly for 
LC-MS/MS analysis. For other tissues, samples were weighed and homogenized in 2 mL 
of distilled water using a handheld homogenizer (Omni International, Kennesaw, GA), 
followed by lyophilization for 48 hours (Labconco, Kansas City, MO). Methanol was 
used to extract curcumin from dried tissues for ~18 hrs at room temperature on a rotary 
extractor. Tissues samples were centrifuged twice, first at 4,000 rpm for 10 minutes and 
then at 14,000 rpm for 8 minutes to eliminate any tissue debris from samples. Final 
supernatant was used directly for LC-MS/MS analysis of curcumin.  
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2.9 Cell Cytotoxicity Studies 
Cells were seeded in 96-well plates at a seeding density of 5,000 per well/100 µL 
medium and incubated in 5% CO2 at 37°C. Following attachment, cells were treated with 
0.1 to 25 µmol/L curcumin dissolved in the growth medium (using 0.1% DMSO) for 72 
hours. Fresh medium containing curcumin was added every day. Cell viability was 
measured using MTS assay. The formazan product formed was quantified by measuring 
the absorbance at 490 nm using a microplate reader (ELx800, BioTek Instruments). The 
mean absorbance for each treatment was determined and then expressed as percent 
viability relative to control (0.1% DMSO-treated group). IC50 values were calculated 
using GraphPad Prism software version 5.01 (GraphPad Software, Inc., La Jolla, CA). 
 
2.10 Western Blotting 
Tumors were homogenized in distilled water using a handheld tissue homogenizer 
(Omni International, Kennesaw, GA). Samples were incubated at 4°C overnight, 
followed by centrifugation at 14,000 rpm for 8 minutes at 4°C. Protein concentrations in 
the supernatant were analyzed by bicinchoninic acid (BCA) assay (Thermo Scientific), 
with bovine serum albumin as the standard. Protein samples (50 µg) were loaded onto 4% 
- 15% SDS-PAGE gel (Bio-Rad Laboratories) and, after electrophoresis, transferred onto 
a nitrocellulose membrane (Whatman) using a Criterion blotter (Bio-Rad Laboratories). 
The membrane was blocked with 5% non-fat dry milk in PBS-Tween 20 (PBST), pH 7.4, 
for 1 hour and incubated with primary antibodies against β-glucuronidase (Aviva 
Systems Biology, San Diego, CA) or β-actin (Sigma-Aldrich) in 5% non-fat dry milk in 
PBST overnight at 4°C. After three 10-minute washes with 0.1% PBST, the membrane 
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was incubated with secondary anti-rabbit IgG conjugated with horseradish peroxidase 
(Cell Signaling) in 5% non-fat dry milk in PBST for 1 hour and then washed thrice again 
with 0.1% PBST. The transferred proteins and band intensities were visualized using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). For 
densitometric quantification, immunoblots were digitized on a flat bed scanner and the 
signal intensities of the visualized bands were quantified using ImageJ and OriginPro 8.1 
(Northampton, MA) software. β-actin served as a loading control. Relative normalized 
expression was calculated by dividing the signal intensity of each band by the staining 
intensity of β-actin in the corresponding lane. 
 
2.11 In Vivo Fluorescence Imaging of β-Glucuronidase Activity 
Athymic immunocompromised nude mice (National Cancer Institute) bearing 
MDA-MB-231 LM2 (also referred to as LM2) were used to correlate the levels of β-
glucuronidase activity according to stage of tumorigenesis. LM2 cells, a derivative of 
MDA-MB-231 human mammary adenocarcinoma cells, were selected for their ability to 
metastasize to lung tissue in vivo [186]. Tumor cells were suspended in cell growth 
medium (106 cells/0.1 mL/mouse) and injected into the fourth mammary fat pad of virgin 
female mice. Tumor size was monitored on alternate days throughout the study. 
Fluorescence imaging was carried out on a Caliper LifeScience (Hopkinton, MA) IVIS® 
Spectrum Instrument when tumor volume reached 100, 400, 700, and 1200 mm3. Mice 
were intravenously injected with 100 µg of NIR-TrapG/mouse in 100 µL of 1X DPBS at 
24 hours prior to imaging. NIR-TrapG, an activity-based NIR-fluorescent 
difluoromethylphenol-glucuronide probe [180], has λex = 710 nm and λem = 780 nm. Data 
	   64 
was analyzed using LivingImage® software. Quantification of the fluorescence was 
performed using ImageJ software (Bethesda, MD).  
 
2.12 Immunohistochemistry to Evaluate β-Glucuronidase Expression 
Immunohistochemistry studies with a human breast carcinoma tissue microarray 
(BRC-961, US Biomax, Rockville, MD) were performed to validate the clinical relevance 
of β-glucuronidase overexpression in chemoprevention by curcumin. BRC-961 consists 
of 96 sample cores representing normal, non-malignant human breast tissue and breast 
carcinoma tissue that range in disease stage (normal tissue, benign tumor, hyperplasia, in 
situ carcinoma, malignant tumor) and sub-type (HER-2+, ER/PR+, triple negative). 
Sample cores were stained with anti-β-glucuronidase antibody (Aviva Systems Biology, 
San Diego, CA), and β-glucuronidase positive staining was detected with EDTA. Stained 
sample cores were evaluated under an optical microscope at x400 magnification, and 
staining intensity of each core was quantified using ImageJ software (Bethesda, MD). 
Percentage of sample core stained was correlated directly with β-glucuronidase 
expression.  
 
2.13 Immunohistochemistry to Evaluate Curcumin Effects on Ki-67, CD-31, and 
Cleaved Caspase-3 Levels  
 Female athymic nude mice bearing MDA-MB-231 xenografted tumors were 
orally dosed once daily for two months with blank SMEDDS, curcumin SMEDDS, or 
remained untreated as described above. Mice were sacrificed when tumor volumes 
reached 1200 mm3 and mammary tissue was collected. Tumor samples were fixed in 10% 
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phosphate-buffered formalin for 24 hours and subsequently transferred to 70% ethanol.  
Tissue processing and staining for Ki-67, CD-31, and cleaved caspase-3 were carried out 
by the Comparative Pathology Shared Resource at the University of Minnesota. All the 
samples were received by the Comparative Pathology Shared Resource laboratory in 70% 
v/v ethanol/water, and processed accordingly for routine histology and embedded in 
paraffin. Samples were cut into 4 µm sections, and after deparaffinization, sections were 
stained with antibodies against Ki-67, CD-31, and cleaved caspase-3. Abnormal tissue 
areas (lobular hyperplasia, carcinoma in situ, and invasive carcinoma) were measured in 
40x magnification photographs using ImageJ software (Bethesda, MD). Ki-67, CD-31, 
and cleaved caspase-3 staining were quantified by taking 15 unique 400x images per 
tissue and using ImageJ software to measure the staining intensity of each image. Results 
are presented as average percent of tissue stained for each biomarker, and staining 
intensity was correlated directly with levels of Ki-67, CD-31, and cleaved caspase-3 
expression. Staining in the central necrotic region of the tumor was excluded from 
analysis.  
 
2.14 HPLC Analysis 
 All HPLC analyses were performed using a Beckman Coulter HPLC system 
attached to UV-PDA and fluorescence (Jasco, Easton) detectors. Sample injection 
volume was 50 µL for all analytes. 
 4-nitrophenol (NP) and 4-nitrophenyl β-D-glucuronide (NPG). The mobile phase 
consisted of 10 mM ammonium acetate buffer adjusted to pH 4.0 using glacial acetic acid 
(A) and acetonitrile (B) running at a flow rate of 1.0 mL/min. The composition of the 
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mobile phase was 45:55 v/v, A:B. Compounds were separated using the Scherzo SM C-
18 column (Imtakt). NPG (λmax = 302 nm) eluted at 3.9 min and NP (λmax = 314 nm) 
eluted at 3.2 min. Total run time was 6 minutes. NPG and NP produced linear standard 
plots over the concentration range of 0.625 – 20 µg/mL with R2 > 0.998 (Figure 2.3). 
 Curcumin. The mobile phase consisted of 10 mM ammonium acetate buffer 
adjusted to pH 4.0 using glacial acetic acid (A) and acetonitrile (B) running at a flow rate 
of 1.0 mL/min. Composition varied as such: 0 min. 20% B, 0-2 min. 20-70% B, 2-4 min. 
70% B, 4-8 min. 70-20% B, 8-9 min. 20% B. The column used was Eclipse XDB C-18 
(150 x 4.6 mm, 5 µm) with an Agilent Zorbax cartridge guard column (C-18, 12.5 x 4.6 
mm). Analytical grade curcumin (retention time, 7.8 min) was detected using a UV-Vis 
detector (excitation λmax = 430 nm). Curcumin produced a linear standard plot over the 
concentration range of 0.015 – 1 µg/mL with R2 > 0.999 (Figure 2.2). 
 
2.15 LC-MS/MS Analysis  
 All LC-MS/MS analyses were performed using an Agilent Technologies 1200 
series system with negative ESI connected to a TSQ Quantum system (Agilent 
Technologies, coupled to Finnigan TSQ Quantum Discovery Max triple quadrupole 
detector, Thermo Electron). Sample injection volume was 5 µL for all analytes. 
 Curcumin and curcumin glucuronide. The mobile phase consisted of (A) 0.1% 
formic acid and (B) acetonitrile. Separation was achieved on an Agilent XDB-C18 
column (50 mm x 4.5 mm internal diamater, 1.8 µm particle size), fitted with an Agilent 
Zorbax cartridge guard column (C-18, 12.5 x 4.6 mm). Linear gradient flow (0.5 
mL/min) with a total run time of 9 min was used: 0-0.5 min: 25% B, 0.5-2.9 min: 25-
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100% B, 2.9-4.9 min: 100% B, 4.9-5.5 min: 100-25% B, 5.5-9 min: 25%. Samples were 
analyzed in positive ion mode. Analytical grade curcumin and curcumin glucuronide 
were monitored using single reaction monitoring of the 369.1 to 176.0 and 545.2 to 368.1 
transitions, respectively. Retention times of curcumin glucuronide and curcumin under 
these conditions were 4.25 and 5.03 minutes, respectively. The chromatographic data 
were acquired and analyzed using Xcaliber software (Thermo Scientific). Curcumin 
produced a linear standard plot over the concentration range of 0.005 – 2.5 µg/mL with 
R2 > 0.996 (Figure 2.4), and curcumin glucuronide produced a linear standard plot over 
the concentration range of 0.005 – 10 µg/mL with R2 > 0.992 (Figure 2.5). 
 
2.16 Determination of Pharmacokinetic Parameters  
Non-compartmental analysis of the drug concentrations was performed using 
Phoenix WinNonlin software version 6.3 (Pharsight, St. Louis, MO). Pharmacokinetic 
parameters for curcumin and curcumin glucuronide disposition were obtained from the 
concentration-time profiles of plasma and tumor tissue in both the TuBo and 4T1 models. 
The area under the concentration-time curve (AUC0-∞) for plasma and tumor were 
calculated using the trapezoidal method. The terminal half-life (t1/2) was determined by 
using the following equation: 
€ 
t1/ 2 =
0.693
k  
 
The terminal rate constant (k) was calculated using Phoenix WinNonlin 6.3.  
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2.17 Statistical Analysis 
 Statistical analyses of observed differences between two groups were performed 
using Student’s two-sample t-test. Comparisons between more than two groups were 
performed using ANOVA followed by Newman-Keuls’ testing, with a probability level 
of p < 0.05 being considered statistically significant. 
 
 
Figure 2.2. Standard Curve for the Quantification of Curcumin by HPLC Analysis. 
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Figure 2.3. Standard Curve for the Quantification of 4-Nitrophenyl β-D-Glucuronide 
and 4-Nitrophenol by HPLC Analysis. 
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Figure 2.4. Standard Curve for the Quantification of Curcumin by LC-MS/MS 
Analysis. 
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Figure 2.5. Standard Curve for the Quantification of Curcumin Glucuronide by LC-
MS/MS Analysis. 
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3.1 β-Glucuronidase Expression According to Breast Cancer Stage and Subtype 
in Human Breast Carcinoma Tissue 
β-glucuronidase expression was determined by immunohistochemistry in human 
breast carcinoma tissue that varied in both breast cancer stage and subtype. 
Representative images of the microarray sample cores stained for β-glucuronidase 
expression are shown in Figure 3.1. Qualitative analysis showed that HER-2+ subtype 
sample cores had the highest levels of staining, followed by triple negative subtype. 
Sample cores consisting of normal, healthy breast tissue revealed barely detectable levels 
of staining for β-glucuronidase expression. Based on the results from the quantitative 
analysis of enzyme expression levels according to subtype, triple positive subtype had the 
lowest β-glucuronidase expression at 2.82 ± 1.14% of the sample core stained. ER/PR+ 
subtype showed slightly higher enzyme levels (5.58 ± 1.45%) than triple positive subtype 
levels. Triple negative and HER-2+ subtypes had the highest β-glucuronidase expression 
levels on average at 11.89 ± 2.96% and 17.25 ± 4.78%, respectively (Figure 3.2).  
Expression of β-glucuronidase was also studied according to breast cancer stage 
of tumorigenesis. Results are displayed as enzyme expression by stage, and within each 
stage, the individual subtypes. As the microarray was limited in the number of samples in 
the earlier stages of breast cancer (i.e., normal, benign, hyperplasia, in situ), the results 
convey only the few sample cores that were represented in each of these stages. The most 
represented stage on the microarray was the malignant (invasive carcinoma/metastatic) 
stage. According to results, the β-glucuronidase expression levels increased as the stage 
advanced, regardless of the subtype. For triple positive subtype, enzyme expression 
increased from normal (0.59 ± 0.09% of sample core stained) to carcinoma in situ (5.87 ± 
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1.87%) and malignant (5.40 ± 2.30%; P<0.05). In ER/PR+ sample cores, β-glucuronidase 
levels increased from normal (2.67 ± 1.07%) and hyperplasia (3.07 ± 1.18%) to 
malignant stage (9.91 ± 2.68; P<0.05). Enzyme levels were shown to be the highest in the 
most advanced malignant stage, with expression levels according to subtype following a 
similar trend as when just the subtype was analyzed alone: triple positive (5.40 ± 2.30%) 
< ER/PR+ (9.91 ± 2.68%) < triple negative (11.89 ± 2.96%) < HER-2+ (16.13 ± 4.59%). 
Once again, HER-2+ subtype showed the highest expression level as compared to other 
subtypes (Figure 3.3).  
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Figure 3.1. Representative images from immunohistochemistry on primary human 
breast tumor tissue stained for β-glucuronidase expression in normal tissue, triple 
negative type, and HER-2+ type breast cancer. Sample cores are from the BRC-961 
microarray from US Biomax, Inc. 
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Figure 3.2. Levels of β-glucuronidase expression (percentage of core stained) in 
sample cores of primary human breast tumor tissue from BRC-961 microarray. β-
glucuronidase expression was quantified according to subtype of breast cancer. Data 
shown are Mean ± SE. * P<0.05 
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Figure 3.3. Levels of β-glucuronidase expression (percentage of core stained) in 
sample cores of primary human breast tumor tissue from BRC-961 microarray. β-
glucuronidase expression was quantified according to stage of breast cancer. Each stage 
was quantified based on breast cancer subtype. Data shown are Mean ± SE. 
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3.2 Normalized β-Glucuronidase Expression in HER-2+ Balb-neuT Model 
The presence of β-glucuronidase protein in mammary tumor tissue of transgenic 
Balb-neuT mice was determined by Western blotting. Mammary tissue and tumors were 
collected at 3, 8, 12, 16, and 23 weeks of age to represent each stage of tumorigenesis, 
ranging from hyperplasia (3 weeks) to metastasis (23 weeks). These studies showed that 
mammary tissue during the earlier stages of tumorigenesis (3, 8, 12 weeks of age) 
showed lower levels of β-glucuronidase than at the more advanced stages of invasive 
carcinoma and metastasis (16, 23 weeks). The normalized protein level at 23 weeks of 
age was found to be, on average, 2.6- and 4.6-fold greater than at 8 and 12 weeks, 
respectively (Figures 3.4 and 3.5).  
 
3.3 Specific Activity of β-Glucuronidase in HER-2+ Transgenic Balb-neuT and 
Wild-Type Balb/c Models According to Stage of Tumorigenesis 
To investigate the hypothesis that β-glucuronidase is overexpressed in the 
mammary tumors as compared to healthy tissue, mammary tissues from wild-type Balb/c 
mice and that from transgenic Balb-neuT mice bearing mammary tumors were studied. 
Tissue from both the wild-type and transgenic strains were extracted from mice at various 
ages to represent the progressive stages of tumorigenesis (n = 3 per stage): 3 weeks 
(hyperplasia), 8 and 12 weeks (carcinoma in situ), 16 weeks (invasive carcinoma), and 23 
(metastasis) weeks of age.  
In the Balb-neuT model, the initial stages of tumorigenesis exhibit low levels of 
β-glucuronidase specific activity. At 3 and 8 weeks of age, mammary tissue yielded 2.58 
± 0.72 and 2.97 ± 0.32 nmol NP formed/hr/mg protein, respectively. By 12 weeks, 
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mammary tumors are further developed and had a specific activity of 5.72 ± 0.90 nmol 
NP formed/hr/mg protein. At 16 weeks, activity levels dropped slightly to 4.31 ± 0.49 
nmol NP formed/hr/mg protein before increasing to 10.71 ± 0.78 nmol NP formed/hr/mg 
protein at 23 weeks of age (Figure 3.6). 
β-glucuronidase specific activity levels in the mammary tissue from the wild-type 
Balb/c model were minimal as compared to that from the Balb-neuT model. Whereas the 
specific activity increased with age and tumor progression in the Balb-neuT model, the 
levels in the Balb/c model were relatively constant: ~1 nmol NP formed/hr/mg protein 
from 3 weeks to 23 weeks of age. The highest activity was observed to be at 16 weeks in 
Balb/c (1.45 ± 0.86 nmol NP formed/hr/mg protein), which was lower than the lowest 
activity in the transgenic model at 3 weeks (2.58 ± 0.72 nmol NP formed/hr/mg protein) 
(Figure 3.6).  
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Figure 3.4. β-glucuronidase expression normalized to total protein in HER-2+ Balb-
neuT mammary tumor tissue at different stages of tumorigenesis, as determined by 
Western blotting. Data shown are Mean ± SE, n = 3. * P<0.05 
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Figure 3.5. β-Glucuronidase expression according to age of mice, which corresponds 
to each stage of tumorigenesis.  Mammary tumor samples from different age groups of 
female transgenic Balb-neuT mice were analyzed for enzyme expression by Western 
blotting. β-Actin served as the protein loading control.  
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Figure 3.6. Specific activity (nmol NP formed/hr/mg protein) of β-glucuronidase in 
HER-2+ transgenic Balb-neuT mammary tumor tissue (orange) and wild-type Balb/c 
healthy mammary tissue (blue). Mammary tissue from wild-type female Balb/c mice and 
mammary tumors from female Balb-neuT mice were collected at 3, 8, 12, 16, and 23 
weeks of age to represent each stage of tumorigenesis. Tissues collected were processed 
for enzyme activity assays. β-glucuronidase activity was determined by monitoring the 
conversion rate of 4-nitrophenyl β-D-glucuronide (NPG) to the parent compound 4-
nitrophenol (NP) for 4 hours of incubation at 37°C. NPG and NP concentrations were 
determined by HPLC. Data shown are Mean ± SE, n = 3. * P<0.05, compared to specific 
activity in Balb-neuT mammary tumor tissue at age groups 3 and 8 weeks; ** P<0.05, 
compared to specific activity in Balb-neuT mammary tumor tissue at age groups 3 – 16 
weeks, ANOVA.  
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3.4 β-Glucuronidase Activity is Present in Tumor Tissue but Absent in Plasma 
from HER-2+ Balb-neuT Model 
To determine whether β-glucuronidase activity is present in plasma – which may 
potentially account for some levels of the active drug being present in the systemic 
circulation – enzyme activity assays were conducted with plasma and compared to tumor 
tissue homogenate data. In the mammary tumor tissue, the amount of NPG decreased by 
12% on average per hour, and after 3 hours of incubation, 61.11 ± 3.62% NPG remained 
in the sample homogenate. Such a significant rate of NPG conversion is indicative of 
high levels of β-glucuronidase present within the tumor. On the contrary, no significant 
conversion of NPG to NP was seen in plasma samples even at the end of 4 hours (Figure 
3.7).  
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Figure 3.7. β-Glucuronidase activity is present in tumor tissue but absent in plasma 
from HER-2+ Balb-neuT model. Enzyme activity was determined by monitoring the 
conversion rate of 4-nitrophenyl β-D-glucuronide (NPG) to the parent compound 4-
nitrophenol (NP) for 3-4 hours of incubation at 37°C. NPG and NP concentrations were 
determined by HPLC. Data shown are Mean ± SD, n = 3.  
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3.5 β-Glucuronidase Activity in HER-2+ Balb-neuT Mammary Tumor Tissue is 
Inhibited by Saccharolactone (GUSB Inhibitor) 
 To ensure that β-glucuronidase is specifically responsible for cleaving the 
glucuronide moeity from NPG and that the decreasing levels of NPG in the enzyme 
activity assays is not a result of spontaneous degradation or other enzymes, 
saccharolactone, a known inhibitor of β-glucuronidase, was used as a control. In Balb-
neuT mammary tumor homogenate without saccharolactone, the amount of NPG 
decreased by 12% on average with each additional hour; after 3 hours of incubation, 61 ± 
3% NPG remained in the homogenate. With the addition of saccharolactone, however, 
the conversion rate was much lower than without the inhibitor. Tumor homogenate 
incubated with saccharolactone had an average NPG activation rate of only 2% per hour. 
After 4 hours, 94.53 ± 2.82% NPG remained in tumor tissue homogenate containing the 
inhibitor (Figure 3.8). This study confirmed that conversion of NPG to NP was 
specifically catalyzed by β-glucuronidase.  
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Figure 3.8. β-Glucuronidase activity in HER-2+ mammary tumor tissue from the 
Balb-neuT mouse model is inhibited by Saccharolactone (GUSB Inhibitor). Enzyme 
activity was determined by monitoring the conversion rate of 4-nitrophenyl β-D-
glucuronide (NPG) to the parent compound 4-nitrophenol (NP) for 3-4 hours of 
incubation at 37°C. NPG and NP concentrations were determined by HPLC. Data shown 
are Mean ± SD, n = 3.  
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3.6 NIR-TrapG: In Vivo β-Glucuronidase Activity Imaging in LM2 Model 
 β-glucuronidase activity in vivo was investigated using an activity-based near-
infrared fluorescent difluoromethylphenol-glucuronide probe (NIR-TrapG). This probe in 
the glucuronidated state has no fluorescence, but becomes fluorescent upon activation by 
β-glucuronidase. The fluorescence detected can in turn be used to identify regions where 
significant β-glucuronidase activity occurs. The goal of this study was to use this probe to 
longitudinally interrogate for regions of high β-glucuronidase activity using live animal 
imaging.  
 According to the resulting data of fluorescence imaging and its quantification, 
significant fluorescent signals were present in not only the tumor, but in the liver region 
as well. Data was presented as average image area of fluorescence, given in the units 
Pixels2. LM2 tumors on average yielded fluorescent signals that increased 
correspondingly with tumor size. Tumor volumes of 100, 400, 700, and 1200 mm3 
showed average fluorescent image areas of 10 ± 0.4 pixels2, 78 ± 2 pixels2, 423 ± 49 
pixels2, and 1056 ± 28 pixels2, respectively (Figures 3.9 and 3.10). The increase in 
fluorescence in tumor was linear with respect to tumor growth. In the case of the liver, 
while the fluorescent signal did increase with tumor volume, the elevation of 
fluorescence levels did not correspond to tumor volume increase as closely as in the case 
of tumor fluorescence. A sudden increase in signals in the liver region was observed from 
400 mm3 (212 ± 8 pixels2) to 700 mm3 (943 ± 168 pixels2). Liver fluorescent signals did 
not increase significantly as tumors grew to 1200 mm3 (1084 ± 242 pixels2).  
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Figure 3.9. Fluorescent probe imaging displaying in vivo β-glucuronidase activity in 
LM2 tumor model. Immunocompromised athymic nude mice were injected 
orthotopically with LM2 cells at 500,000 cells/mouse and tumors were grown to 100, 
400, 700 and 1200 mm3. At each volume, mice were administered NIR-TrapG (100 µg), 
a glucuronidated probe that becomes fluorescent upon activation by β-glucuronidase, and 
animals were imaged for fluorescence at 24 hours post-dose.  
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Figure 3.10. Average image area of fluorescence (Pixels2) in liver and tumor of LM2 
tumor model. Immunocompromised athymic nude mice were injected orthotopically with 
LM2 cells at 500,000 cells/mouse and tumors were grown to 100, 400, 700 and 1200 
mm3. At each volume, mice were administered NIR-TrapG (100 µg), a glucuronidated 
probe that becomes fluorescent upon activation by β-glucuronidase, and animals were 
imaged for fluorescence at 24 hours post-dose. Data shown are Mean ± SE, n = 3.  
* P<0.05, compared to fluorescence in tumor at 400 mm3; ** P<0.05, compared to 
fluorescence in tumor at 700 mm3, ANOVA. 
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3.7 Specific Activity of β-Glucuronidase in Mammary Tumor Models:   
JC, TuBo, MDA-MB-231, 4T1 
 Different breast cancer subtypes and cell lines are known to vary in aggression. 
Four mammary tumor models were used for these studies: JC (triple negative, syngeneic 
to Balb/c), TuBo (HER-2+, syngeneic to Balb/c), MDA-MB-231 (triple negative, human 
adenocarcinoma), and 4T1 (triple negative, syngeneic to Balb/c). Mammary tissue from 
wild-type Balb/c mice and tumors from the orthotopic models were collected at 100, 400, 
700, and 1200 mm3 to measure β-glucuronidase specific activity levels.  
 Results show that β-glucuronidase specific activity increased with tumor size up 
to 400 mm3 for all models (Figure 3.11). At 400 mm3 and above, specific activity levels 
did not increase further with tumor volume growth. Wild-type Balb/c mammary tissue 
had β-glucuronidase specific activity levels ranging from 0.74 ± 0.40 to 1.16 ± 0.73 nmol 
NP formed/hr/mg protein. TuBo tumors showed the lowest levels of β-glucuronidase 
activity in comparison to the other 3 models. At 100 mm3, activity levels were at 0.31 ± 
0.09 nmol NP formed/hr/mg protein and at 1200 mm3, levels increased to 1.47 ± 0.03 
nmol NP formed/hr/mg protein. These activity levels, however, were much lower than 
the other 3 triple negative models. In MDA-MB-231, JC, and 4T1 tumors at 100 mm3, 
specific activities were 2.70 ± 0.32, 2.85 ± 0.43, and 2.06 ± 0.08 nmol NP formed/hr/mg 
protein, respectively. Levels increased to 4.33 ± 0.77 nmol NP formed/hr/mg protein for 
MDA-MB-231, 5.10 ± 0.65 nmol NP formed/hr/mg protein for JC, and 5.17 ± 0.74 nmol 
NP formed/hr/mg protein for 4T1. The 4T1 model exhibited the highest β-glucuronidase 
specific activity, which may be due to its aggressiveness in terms of cell growth, 
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proliferation, tumor formation, and increased infiltration of inflammatory cells such as 
macrophages and neutrophils [114].  
Lungs are a common site for breast cancer metastasis. There is strong potential for 
the presence of β-glucuronidase activity in metastatic lesions as well as in primary 
tumors. Due to the aggressiveness of the 4T1 model and high β-glucuronidase specific 
activity, lungs from Balb/c mice bearing 4T1 tumors in the later stages (>1200 mm3) and 
from wild-type Balb/c mice of the same age were collected and analyzed for enzyme 
activity levels. Lungs extracted from 4T1 tumor bearing mice had significantly greater β-
glucuronidase activity than those from wild-type Balb/c mice (1.97 ± 0.17 versus 1.26 ± 
0.14 nmol NP formed/hr/mg protein; P<0.05) (Figure 3.12). These results support the 
proposition that metastatic sites may also overexpress β-glucuronidase, suggesting that 
distant metastatic sites may also be capable of glucuronide prodrug activation.  
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Figure 3.11. Specific activity (nmol NP formed/hr/mg protein) of β-glucuronidase in 4 
mammary tumor models. Female Balb/c mice were injected orthotopically with JC, 
TuBo, 4T1, and MDA-MB-231 cells at 1,000,000 cells/mouse and tumors were grown to 
100, 400, 700 and 1200 mm3. At each volume, tumors were collected and processed for 
enzyme activity assays. β-glucuronidase activity was determined by monitoring the 
conversion rate of 4-nitrophenyl β-D-glucuronide (NPG) to the parent compound 4-
nitrophenol (NP) for 4 hours of incubation at 37°C. NPG and NP concentrations were 
determined by HPLC. Data shown are Mean ± SE, n = 3. * P<0.05, compared to specific 
activities at 0 mm3 and 100 mm3, ANOVA. 
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Figure 3.12. Specific activity (nmol NP formed/hr/mg protein) of β-glucuronidase in 
lungs from 4T1 model. Female Balb/c mice were injected orthotopically with 4T1 cells at 
1,000,000 cells/mouse and tumors were grown to 1200 mm3. Lungs were collected and 
processed for enzyme activity assays. β-glucuronidase activity was determined by 
monitoring the conversion rate of 4-nitrophenyl β-D-glucuronide (NPG) to the parent 
compound 4-nitrophenol (NP) for 4 hours of incubation at 37°C. NPG and NP 
concentrations were determined by HPLC. Data shown are Mean ± SE, n = 3. * P<0.05, 
ANOVA.  
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3.8 Chemopreventive Efficacy of Oral Curcumin in Mammary Tumor Models:  
JC, TuBo, MDA-MB-231, 4T1 
 The chemopreventive efficacy of orally dosed curcumin in a microemulsion 
formulation was evaluated in four different mammary tumor models: JC, TuBo, MDA-
MB-231, and 4T1. Tumor bearing mice were orally administered curcumin in a self-
microemulsifying drug delivery system (SMEDDS) formulation at 100 mg/kg daily 
beginning one day prior to cell injection, and the once daily dosing lasted until the end of 
the study. All the tumor models, except for TuBo, showed reduced tumor growth rate 
with the curcumin microemulsion treatment. At the end of a month-long study with 
TuBo, tumor volumes across all three treatment groups were similar. While the curcumin 
SMEDDS treated group (582 ± 69 mm3) had an average tumor volume lower than that of 
the blank SMEDDS (815 ± 101 mm3) and the untreated (748 ± 69 mm3) groups, the 
difference between the groups was not statistically significant (Figure 3.14).  
 In the other three models, the curcumin SMEDDS treated group had statistically 
significant lower tumor growth rates than the blank SMEDDS and untreated groups. In 
the JC model, the curcumin SMEDDS group (515 ± 89 mm3) had a lower average tumor 
volume at the end of the month-long study when compared to the blank SMEDDS (932 ± 
79 mm3) and untreated (856 ± 116 mm3) groups (P<0.05) (Figure 3.13). Similar was the 
case with the 4T1 model, where the curcumin SMEDDS treated group (1199 ± 180 mm3) 
had a significantly lower volume at the end of the study than the blank SMEDDS treated 
group (1886 ± 126 mm3) (P<0.05) (Figure 3.15). However, the difference was not 
statistically significant when the curcumin treated group was compared with the untreated 
group, which had a final average volume of 1487 ± 186 mm3. This lack of significance 
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between the curcumin treated and untreated groups, as well as the overall higher volumes 
of the 4T1 tumors in all the three treatment groups at one month post-inoculation, could 
be attributed to the aggressive nature of the 4T1 model.  
The MDA-MB-231 model proved to be the most responsive to oral curcumin 
treatment, as shown by the significantly lower tumor volume of the curcumin SMEDDS 
treated group at the end of a 2-month long efficacy study as compared to the other control 
treatment groups (Figure 3.16). This data is quite notable, as efficacy is shown in a 
human tumor xenograft model. At 2 months, the mean tumor volume in the curcumin 
SMEDDS treatment group was 41.9% lower than that of the blank SMEDDS treated 
group (819 ± 147 mm3 versus 1951 ± 148 mm3, respectively).  
 The weights of mice in each of the three experimental treatment groups were 
monitored throughout the study to assess potential systemic toxicity effects due to drug 
and microemulsion treatment. Both the blank and curcumin SMEDDS treatments did not 
cause any gross toxicity, as the body weights were either relatively constant (TuBo 
model) or increased slightly (4T1 and MDA-MB-231 models) throughout the course of 
the study (Figures 3.17). JC was the only one model in which average weights slightly 
decreased, but since the decrease was <10% from the beginning to the end of the study, 
the treatments were still deemed safe.  
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Figure 3.13. Oral dosing of curcumin SMEDDS formulation inhibits JC tumor growth 
rate. Female Balb/c mice were injected orthotopically with JC cells at 1,000,000 
cells/mouse and dosed orally with curcumin daily at 100 mg/kg (n=6 per group: curcumin 
SMEDDS, blank SMEDDS, untreated). Treatments began 1 day prior to injection of 
tumor cells. Points, mean (n=6); bars, SE. P<0.05, ANOVA. 
 
 
 
 
 
 
	   97 
 
 
 
Figure 3.14. Oral dosing of curcumin SMEDDS formulation has no significant effect 
on TuBo tumor growth rate. Female Balb/c mice were injected orthotopically with TuBo 
cells at 1,000,000 cells/mouse and dosed orally with curcumin daily at 100 mg/kg (n=6 
per group: curcumin SMEDDS, blank SMEDDS, untreated). Treatments began 1 day 
prior to injection of tumor cells. Points, mean (n=6); bars, SE.  
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Figure 3.15. Oral dosing of curcumin SMEDDS formulation has no significant effect 
on 4T1 tumor growth rate. Female Balb/c mice were injected orthotopically with 4T1 
cells at 1,000,000 cells/mouse and dosed orally with curcumin daily at 100 mg/kg (n=6 
per group: curcumin SMEDDS, blank SMEDDS, untreated). Treatments began 1 day 
prior to injection of tumor cells. Points, mean (n=6); bars, SE. P<0.05, ANOVA. 
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Figure 3.16. Oral dosing of curcumin SMEDDS formulation inhibits MDA-MB-231 
tumor growth rate. Female athymic nude mice were injected orthotopically with MDA-
MB-231 cells at 1,000,000 cells/mouse and dosed orally with curcumin daily at 100 
mg/kg (n=6 per group: curcumin SMEDDS, blank SMEDDS, untreated). Treatments 
began 1 day prior to injection of tumor cells. Points, mean (n=6); bars, SE. P<0.05, 
ANOVA. 
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Figure 3.17.a.    Average mouse weights of mice from chemopreventive efficacy studies. 
Female Balb/c mice were injected orthotopically with JC and TuBo cells at 1,000,000 
cells/mouse and dosed orally with curcumin daily at 100 mg/kg (n=6 per group: curcumin 
SMEDDS, blank SMEDDS, untreated). Treatments began 1 day prior to injection of 
tumor cells. Points, mean (n=6); bars, SE. P<0.05, ANOVA. 
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Figure 3.17.b.    Average mouse weights of mice from chemopreventive efficacy studies. 
Female Balb/c mice were injected orthotopically with 4T1 and MDA-MB-231 cells at 
1,000,000 cells/mouse and dosed orally with curcumin daily at 100 mg/kg (n=6 per 
group: curcumin SMEDDS, blank SMEDDS, untreated). Treatments began 1 day prior to 
injection of tumor cells. Points, mean (n=6); bars, SE. P<0.05, ANOVA. 
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3.9 Curcumin Cytotoxicity in JC, TuBo, MDA-MB-231, 4T1 
The cytotoxic effects of curcumin were evaluated in vitro in four breast 
adenocarcinoma cell lines to determine cellular response to curcumin treatment. As 
shown in Figure 3.18, curcumin caused a dose-dependent cytotoxicity in all the cell lines 
studied. At ~14 µM curcumin treatment, JC, MDA-MB-231, and 4T1 cells are less than 
10% viable, and at a doubled concentration of ~28 µM, these 3 cell lines exhibited 0% 
viability. TuBo cells, however, were more resistant to curcumin treatment. At a 
concentration of ~14 µM, 50 ± 5% of TuBo cells were viable, and at ~28 µM – a high 
enough concentration to completely eradicate the other three cell types in vitro – 20 ± 2% 
of TuBo cells remained viable. This resistance to curcumin treatment in TuBo cells was 
also reflected in IC50 values. TuBo was calculated to have the highest IC50 value of 6.40 
µM, as compared to 4T1, MDA-MB-231, and JC having values of 4.71, 5.39, and 4.68 
µM, respectively (Figure 3.18).  
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Figure 3.18. Curcumin cytotoxicity and IC50 values of various breast cancer cell lines 
for curcumin. Cells were treated with 0.1 – 10 µmol/L curcumin for 72 hours. Cell 
viability was measured using MTS assay, and the results were expressed as percent 
viability relative to control. Points, mean (n=6); bars, SE. 
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3.10 β-Glucuronidase Activity Occurs in the Extracellular Matrix 
To determine whether β-glucuronidase activity occurs intracellularly or 
extracellularly, enzyme activity assays were performed with six breast adenocarcinoma 
cell lines: JC, TuBo, MDA-MB-231, MCF-7, 4T1, and SKBR3. Both intact cells and cell 
lysates of each cell line were studied. According to the results of the assay, all six cell 
lines had ~100% of NPG remaining for both intact cells and cell lysates after 2 hours of 
incubation at 37°C. There was no statistical difference in percent NPG remaining 
between incubation with the six cell lines and a negative control (PBS), indicating that 
negligible amounts, if any, of the NPG was converted to parent NP. To ensure that NPG 
conversion could be detected by this method of analysis, a positive control was included. 
Incubation of NPG with β-glucuronidase from Helix pomatia (Sigma-Aldrich) for 2 hours 
at 37°C resulted in 8.64 ± 2.16% and 18.00 ± 4.44% remaining by direct incubation and 
the freeze-thaw method, respectively (Figure 3.19).  
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Figure 3.19. No intracellular β-Glucuronidase activity is present in intact cells and cell 
lysates. Enzyme activity was determined by monitoring the conversion rate of 4-
nitrophenyl β-D-glucuronide (NPG) to the parent compound 4-nitrophenol (NP) in intact 
cells and cell lysates from 6 breast adenocarcinoma cell lines for 2 hours of incubation at 
37°C. NPG and NP concentrations were determined by HPLC. Data shown are Mean ± 
SD, n = 6.  
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3.11 No Significant β-Glucuronidase Activity in MDA-MB-231 Cells in Hypoxia 
 Tumor hypoxia is the condition in which tumor cells are deprived of oxygen. Due 
to the rapid growth of tumors, the vasculature within the tumor tissue becomes highly 
dysregulated and therefore many regions are exposed to low oxygen levels (hypoxia) 
[181]. Because hypoxic microenvironments are a common phenomenon within a tumor, 
these conditions may affect the β-glucuronidase levels and activity of tumor cells 
subjected to hypoxia. β-glucuronidase activity assays were conducted on MDA-MB-231 
breast adenocarcinoma cells that were subjected to hypoxic conditions in culture to 
determine whether a low-oxygen environment would have an effect on their β-
glucuronidase activity in vitro. Results showed that after 1 and 3 hours of incubation with 
NPG, 102.29 ± 6.5% and 92.67 ± 7.02% of NPG remained, respectively (no statistical 
difference) (Figure 3.20). After 3 hours of incubation, no detectable amount of parent NP 
was observed. Thus, it was concluded that since negligible amounts of NPG were 
converted and that no formation of parent NP was detected after 3 hours of incubation 
with cells in hypoxia, low-oxygen conditions do not induce or affect β-glucuronidase 
activity levels in intact tumor cells.  
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Figure 3.20. No significant β-Glucuronidase activity in MDA-MB-231 cells in 
hypoxia. Enzyme activity was determined by monitoring the conversion rate of 4-
nitrophenyl β-D-glucuronide (NPG) to the parent compound 4-nitrophenol (NP) for 3 
hours of incubation under hypoxic conditions (<5% O2) at 37°C. NPG and NP 
concentrations were determined by HPLC. Data shown are Mean ± SD, n = 3. 
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3.12 Pharmacokinetic Study I:  Curcumin SMEDDS Oral Dosing in 4T1 and 
TuBo Tumor-Bearing Balb/c Mice 
According to our prodrug activation hypothesis, curcumin glucuronide is the 
predominant form of curcumin present in the plasma following oral administration of 
curcumin. Upon reaching the tumor microenvironment, β-glucuronidase present in the 
tumor extracellular matrix hydrolyzes curcumin glucuronide, yielding active curcumin at 
the site of action. This hypothesis was tested through evaluation of the pharmacokinetics 
and biodistribution of curcumin and its metabolite curcumin glucuronide. Healthy female, 
wild-type Balb/c mice and female mice bearing orthotopic tumors (4T1 or TuBo) were 
either dosed orally with curcumin SMEDDS or intravenously with curcumin glucuronide 
directly into the systemic circulation. 4T1 and TuBo models were chosen for these 
pharmacokinetic studies due to their high and low β-glucuronidase specific activities, 
respectively, as shown in the tumor homogenate studies. Wild-type Balb/c mice served as 
the control. Curcumin glucuronide was injected intravenously to study metabolite 
pharmacokinetics without the absorption barrier. 
The first study investigated curcumin and curcumin glucuronide pharmacokinetics 
following a single oral dose of curcumin SMEDDS at 100 mg/kg in 4T1 (Figure 3.21) 
and TuBo (Figure 3.22) models. Curcumin glucuronide levels were significantly higher 
than that of curcumin in plasma, and the profiles of the glucuronide were similar between 
the two tumor models. Even though maximum concentrations were different between 
4T1 (Cmax = 62.77 µg/mL) and TuBo (Cmax = 46.97 µg/mL), plasma concentration-time 
profiles were similar, and the two AUC0-∞ were practically identical: AUC0-∞ in 4T1 = 
178.46 µg*hr/mL; AUC0-∞ in TuBo = 177.32 µg*hr/mL. The elimination half-lives were 
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also nearly the same for curcumin glucuronide; after non-compartmental analysis, t1/2 was 
estimated to be 3.86 hours in the 4T1 model and 3.97 hours in the TuBo model. These 
concentration-time profiles show that, following oral curcumin delivery, the glucuronide 
levels in plasma are independent of the tumor model. 
However, curcumin levels in the tumor tissue were different for the two tumor 
models. The AUC0-∞ and Cmax for curcumin in the 4T1 model was significantly higher 
than that in the TuBo model. After non-compartmental analysis, Cmax of curcumin in 4T1 
was determined to be 104.87 ng/g, whereas in TuBo, Cmax was 62.95 ng/g. The higher 
curcumin levels in 4T1 tumors were also reflected by the calculated AUC0-∞ values, in 
which AUC0-∞ for 4T1 was 476.47 ng*hr/g, while AUC0-∞ for TuBo was lower at 370.30 
ng*hr/g. The average t1/2 for curcumin elimination from the tumor was determined to be 
40.53 hours for both models.  
Liver concentrations of curcumin were highly variable and did not follow any 
type of trend. In the liver of 4T1 tumor-bearing mice, curcumin levels ranged from 0.95 
ng/g to 5873.42 ng/g; in TuBo tumor-bearing mice, levels ranged from 2.34 ng/g to 
2775.60 ng/g. Curcumin glucuronide concentrations were negligible in the liver for both 
models.  
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Figure 3.21. Concentration-time profiles of curcumin and its metabolite curcumin 
glucuronide in (A) plasma, (B) tumor, and (C) liver of 4T1 tumor bearing mice following 
a single oral dose of curcumin SMEDDS formulation (100 mg/kg). Curcumin and 
curcumin glucuronide concentrations were determined by LC-MS/MS. Points, mean (n = 
3-4); bars, SE. 
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Figure 3.22. Concentration-time profiles of curcumin and its metabolite curcumin 
glucuronide in (A) plasma, (B) tumor, and (C) liver of TuBo tumor bearing mice 
following a single oral dose of curcumin SMEDDS formulation (100 mg/kg). Curcumin 
and curcumin glucuronide concentrations were determined by LC-MS/MS. Points, mean 
(n = 3-4); bars, SE. 
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3.13 Pharmacokinetic Study II:  Curcumin Glucuronide Intravenous Dosing in 
4T1 and TuBo Tumor-Bearing Balb/c Mice 
Since curcumin glucuronide is the primary metabolite that is present in plasma 
following oral dosing, the pharmacokinetics of the glucuronide itself was investigated. 
The second study evaluated curcumin and curcumin glucuronide pharmacokinetics 
following a single intravenous dose of curcumin glucuronide at 2 mg/kg in both 4T1 
(Figure 3.23) and TuBo (Figure 3.24) models. As in the case with oral dosing of 
curcumin SMEDDS, curcumin glucuronide concentrations in plasma were consistent 
between the two tumor models. Elimination half-lives were virtually the same – 3.93 
hours in 4T1 and 3.98 hours in TuBo. Tmax and Cmax were almost identical as well: Tmax = 
0.25 hours for both models; Cmax (or C0.25) for 4T1 = 21.81 µg/mL and Cmax for TuBo = 
23.32 µg/mL. Based on non-compartmental analysis, Co was estimated to be 48.26 
µg/mL for 4T1 and 52.01 µg/mL for TuBo. AUC0-∞ values were 22.70 µg*hr/mL for 4T1 
and 22.80 µg*hr/mL for TuBo. These results confirm that regardless of the tumor model 
and whether curcumin glucuronide is metabolically released into the systemic circulation 
or dosed directly into the systemic circulation, the metabolite exhibits similar 
pharmacokinetics. Curcumin levels in plasma were negligible.  
Curcumin concentration levels in the tumor and lungs were similar in both 4T1 
and TuBo models following an intravenous dose of the glucuronide. In the two models, 
curcumin levels in tumor started off low at early time points (0.25 – 4 hours) but then 
increased to a steady concentration that plateaued off (> 8 hours) at approximately 30 ng 
of curcumin per gram of tumor tissue. Similar was the case in lungs, although curcumin 
concentrations were initially higher (30 – 50 ng/g) at earlier time points of 0 to 2 hours, 
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but then steadied off after 4 hours post-intravenous dose at ~30 ng/g. Curcumin 
glucuronide levels in the tumor and lungs were significantly lower than that of parent 
curcumin.  
Liver concentration levels of both curcumin and curcumin glucuronide were 
minimal on average as compared to plasma and other tissues. With the exception of 
curcumin glucuronide levels at 15 minutes post-intravenous dose for 4T1, which had a 
concentration of 8.35 ng/g, both compounds were found to be at concentration levels of 
<6 ng/g in both models.  
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Figure 3.23. Concentration-time profiles of curcumin and its metabolite curcumin 
glucuronide in (A) plasma, (B) tumor, (C) lung, and (D) liver of 4T1 tumor bearing mice 
following a single intravenous dose of curcumin glucuronide dissolved in 80:20 
DPBS:DMSO mixture (2 mg/kg). Curcumin and curcumin glucuronide concentrations 
were determined by LC-MS/MS. Points, mean (n = 3-4); bars, SE. 
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Figure 3.24. Concentration-time profiles of curcumin and its metabolite curcumin 
glucuronide in (A) plasma, (B) tumor, (C) lung, and (D) liver of TuBo tumor bearing 
mice following a single intravenous dose of curcumin glucuronide dissolved in 80:20 
DPBS:DMSO mixture (2 mg/kg). Curcumin and curcumin glucuronide concentrations 
were determined by LC-MS/MS. Points, mean (n = 3-4); bars, SE. 
 
 
3.14 Pharmacokinetic Study III:  Curcumin Glucuronide Intravenous Dosing in 
Wild-Type Balb/c Mice 
 To assess whether the tumor presence in an animal model would have an effect on 
the biodistribution of curcumin and curcumin glucuronide, a third pharmacokinetic study 
was conducted in which healthy, wild-type female Balb/c mice received a single 
intravenous dose of curcumin glucuronide at 2 mg/kg (Figure 3.25). Results showed the 
concentration-time profile for curcumin glucuronide in wild-type Balb/c mice to be 
nearly identical to the profiles of glucuronide in tumor-bearing mice. Like in the 4T1 and 
TuBo models, curcumin levels in plasma were minimal as compared to the curcumin 
glucuronide levels. These data suggest that since the pharmacokinetic profiles and 
parameters of curcumin glucuronide are consistent between the healthy and tumor-
bearing animals, the disease status of the animal does not affect the biodistribution of 
curcumin glucuronide.  
 Curcumin levels in healthy mammary tissue of the female wild-type mice proved 
to be significantly lower than in the tumor of the 4T1 and TuBo models when dosed 
intravenously with curcumin glucuronide. In the wild-type mammary tissue, curcumin 
levels fall to <10 ng/g at 2 hours and beyond, as opposed to steady concentrations of ~30 
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ng/g in the tumor tissue in the 4T1 and TuBo models at similar time points. The lower 
concentration levels of curcumin in healthy mammary tissue as opposed to higher levels 
in tumor tissue is consistent with the comparatively lower and higher specific activity 
levels of β-glucuronidase in healthy and tumor-bearing mice, respectively, which strongly 
supports the prodrug hypothesis.  
 Lung and liver concentrations of curcumin in healthy mice were highly variable 
when dosed with curcumin glucuronide intravenously. Curcumin concentrations in lungs 
ranged from 1.59 ng/g to 749.21 ng/g; curcumin levels in liver ranged from 2.85 ng/g to 
468.25 ng/g. While curcumin glucuronide in the lungs and liver exhibited a standard 
elimination curve according to the concentration-time profiles, the glucuronide levels 
were significantly lower than that of curcumin in both organs. 
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Figure 3.25. Concentration-time profiles of curcumin and its metabolite curcumin 
glucuronide in (A) plasma, (B) mammary, (C) lung, and (D) liver of wild-type Balb/c 
mice following a single intravenous dose of curcumin glucuronide dissolved in 80:20 
DPBS:DMSO mixture (2 mg/kg). Curcumin and curcumin glucuronide concentrations 
were determined by LC-MS/MS. Points, mean (n = 3-4); bars, SE. 
 
 
 
 
 
 
D	  
	   124 
3.15 Accumulated Curcumin Concentrations in Tumor Tissue from Transgenic 
Balb-neuT and Orthotopic Models: JC (Triple Negative) and TuBo (HER-2+) 
 Curcumin is capable of long-term tissue accumulation due to its hydrophobic 
nature, which can be beneficial in exerting its therapeutic effects at the target site. In 
these set of studies, female transgenic Balb-neuT mice bearing spontaneously-formed 
tumors and wild-type female Balb/c mice bearing orthotopically implanted JC and TuBo 
tumors were orally administered chronic doses of curcumin SMEDDS formulation. Balb-
neuT mice received oral doses at 100 mg/kg for 5 consecutive days, and orthotopic 
models received the same daily dose over a period of one month. At the end of the study, 
tumor tissue and plasma were collected and analyzed for accumulated curcumin 
concentrations by HPLC. In Balb-neuT mice, 0.517 ± 0.145 µM of curcumin 
accumulated in the tumor after 5 days of receiving daily oral doses (Figure 3.26). 
However, no curcumin was detected in the plasma of the same mice. Similar was the case 
with the orthotopic JC and TuBo models in terms of curcumin accumulation ratio 
between tumor and plasma. TuBo tumors accumulated 0.755 ± 0.079 µM and JC 
accumulated 0.095 ± 0.057 µM of curcumin in tumor, whereas plasma concentrations 
were comparatively negligible: 0.007 ± 0.002 µM in TuBo and 0.005 ± 0.004 µM in JC 
(Figure 3.27).   
Interestingly, HER-2+ subtype transgenic Balb-neuT and orthotopic TuBo models 
had a 5.5-fold and 8.0-fold higher accumulation of curcumin in tumor, respectively, as 
compared to triple negative orthotopic JC model. This could be due to higher infiltration 
of inflammatory cells such as macrophages and neutrophils. Such cells would in turn 
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release elevated levels of β-glucuronidase, and hence greater activation and accumulation 
of curcumin in this subtype as compared to the triple negative (JC) model.   
 
 
 
Figure 3.26. Accumulated curcumin concentrations in tumor tissue and plasma from 
HER-2+ transgenic Balb-neuT model. Female Balb-neuT mice bearing mammary tumors 
were orally dosed with curcumin SMEDDS formulation at 100 mg/kg for 5 consecutive 
days prior to tissue and plasma collection. Curcumin concentrations were determined by 
HPLC. Data shown are Mean ± SE, n = 3.  
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Figure 3.27. Accumulated curcumin concentrations in tumor tissue and plasma from 
orthotopic models: JC (triple negative) and TuBo (HER-2+). Female Balb/c mice bearing 
JC and TuBo orthotopic tumors were orally dosed daily with curcumin SMEDDS 
formulation at 100 mg/kg for 1 month prior to tissue and plasma collection. Curcumin 
concentration was determined by HPLC. Data shown are Mean ± SE, n = 3.  
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3.16 Accumulation of Curcumin and Curcumin Glucuronide in Mammary Tissue 
from Wild-Type Balb/c and Tumor Tissue from Orthotopic 4T1 Mouse Models 
after Single and Multiple Dosing of Curcumin SMEDDS 
 Accumulation of curcumin and curcumin glucuronide was evaluated in mammary 
tissue, liver, and plasma of wild-type Balb/c mice and in 4T1 tumor-bearing mice that 
received once-daily, oral doses of curcumin SMEDDS formulation for 14 consecutive 
days. Plasma and tissue were collected at 1 hour post-dose on the last day of the study. 
Plasma levels of curcumin glucuronide were practically the same between the wild-type 
(16.76 ± 2.99 µg/mL) and 4T1 tumor-bearing (15.08 ± 7.50 µg/mL) mice. No detectable 
levels of curcumin were found in plasma (Figure 3.28.a.). In tumor tissue from the 4T1 
model, nearly 15-fold higher levels of curcumin (149.80 ± 18.00 ng/g) were present as 
compared to that in the mammary tissue of wild-type mice (10.52 ± 2.10 ng/g) (P<0.05). 
Curcumin glucuronide followed a similar trend in these tissues, although levels were 
much lower than that of curcumin (Figure 3.28.b.). In the liver, curcumin glucuronide 
levels were also higher in the 4T1 model (244.23 ± 25.95 ng/g) than in the wild-type 
model (116.04 ± 10.55 ng/g) (Figure 3.28.c.).  
 The degree of curcumin accumulation in the tumor tissue of 4T1 tumor-bearing 
mice after having received a single dose or fourteen daily doses of oral curcumin 
SMEDDS was compared. Results showed that chronic dosing of the curcumin SMEDDS 
formulation over a period of two weeks yielded significantly higher levels of curcumin in 
tumor as opposed to just a single dose. The group of tumor-bearing mice receiving 
multiple doses had an average curcumin concentration of 138.53 ± 20.04 ng/g in tumor as 
compared to the group receiving only a single, one-time dose, which had an average 
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concentration of 100.78 ± 10.30 ng/g (P<0.05). Curcumin glucuronide concentrations in 
tumor were much lower (<15 ng/g) in both groups (Figure 3.29).  
 
 
 
 
Figure 3.28.a.    Curcumin and curcumin glucuronide concentrations in plasma from 
wild-type Balb/c and orthotopic 4T1 mouse models. Female wild-type Balb/c mice and 
4T1 tumor bearing mice were orally dosed daily with curcumin SMEDDS formulation at 
100 mg/kg for 14 days prior to tissue and plasma collection. Curcumin and curcumin 
glucuronide concentrations were determined by LC-MS/MS. Data shown are Mean ± SE, 
n = 5.  
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Figure 3.28.b.    Accumulated curcumin and curcumin glucuronide concentrations in 
mammary tissue from wild-type Balb/c and tumor tissue from orthotopic 4T1 mouse 
models. Female wild-type Balb/c mice and 4T1 tumor bearing mice were orally dosed 
daily with curcumin SMEDDS formulation at 100 mg/kg for 14 days prior to tissue and 
plasma collection. Curcumin and curcumin glucuronide concentrations were determined 
by LC-MS/MS. Data shown are Mean ± SE, n = 5. * P<0.05, compared to curcumin 
concentrations in the 4T1 model, ANOVA. 
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Figure 3.28.c.    Accumulated curcumin and curcumin glucuronide concentrations in 
liver tissue from wild-type Balb/c and orthotopic 4T1 mouse models. Female wild-type 
Balb/c mice and 4T1 tumor bearing mice were orally dosed daily with curcumin 
SMEDDS formulation at 100 mg/kg for 14 days prior to tissue and plasma collection. 
Curcumin and curcumin glucuronide concentrations were determined by LC-MS/MS. 
Data shown are Mean ± SE, n = 5.  
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Figure 3.29. Accumulated curcumin and curcumin glucuronide concentrations in tumor 
tissue from orthotopic 4T1 mouse model after single and multiple oral doses of curcumin 
SMEDDS. 4T1 tumor bearing female mice received either a single dose or multiple doses 
of curcumin SMEDDS formulation daily at 100 mg/kg for 14 days prior to tissue and 
plasma collection. Curcumin and curcumin glucuronide concentrations were determined 
by LC-MS/MS. Data shown are Mean ± SE, n = 4. * P<0.05, compared to curcumin 
concentrations after one single dose, ANOVA. 
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3.17 Curcumin Downregulates Markers of Cell Proliferation, Angiogenesis, and 
Induces Apoptosis 
 To understand the underlying mechanisms of improved anticancer efficacy 
following multiple oral dosing of curcumin SMEDDS, MDA-MB-231 tumors from the 
chemopreventive efficacy study were analyzed for biomarkers of cell proliferation (Ki-
67), angiogenesis (CD-31), and apoptosis (cleaved caspase-3). Curcumin SMEDDS 
treatment significantly reduced cell proliferation, as evidenced by percent of tissue 
stained with Ki-67 in tumors of mice receiving curcumin SMEDDS treatment (14.10 ±  
0.93%) as compared to receiving blank SMEDDS (20.40 ± 1.29%) or no treatment (16.36 
± 0.88%) (P<0.05) (Figure 3.30). Similar was the case with microvessel density within 
the tumor. Microvessel density was more pronounced in blank SMEDDS (1.12 ± 0.11%) 
and untreated (0.76 ± 0.07%) treated tumors than in those receiving curcumin SMEDDS 
(0.46 ± 0.04%) (P<0.001). The CD-31 positive microvessels were smaller in size and less 
developed in the curcumin SMEDDS treated group than those in the other control groups 
(Figure 3.31). The trends were inverse in the case of cleaved caspase-3, a biomarker of 
apoptosis. Treatment with curcumin SMEDDS induced cleaved caspase-3 levels in tumor 
by average of greater than 7-fold compared to that caused by blank SMEDDS treatment 
and greater than 2-fold as compared to the untreated group (Figure 3.32). These results 
from immunohistological analysis support that orally dosed curcumin in a microemulsion 
formulation reduces tumor growth rate by inhibiting cell proliferation and angiogenesis 
as well as by inducing apoptosis.  
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Figure 3.30. Curcumin SMEDDS treatment decreases cell proliferation in mammary 
tumor tissue. Female athymic nude mice bearing MDA-MB-231 human tumor xenografts 
were dosed daily at 100 mg/kg with (A) blank SMEDDS formulation, (B) curcumin 
SMEDDS formulation, or (C) remained untreated. Mice were sacrificed at 2 months after 
the initial dose and mammary tissue was stained with anti-Ki-67 antibody. (D) Positive 
Ki-67 staining was quantified as percentage stained per field of view at x400 
magnification using ImageJ software. Scale bars represent 100 µm. Data are presented as 
average percentage of Ki-67 positive staining per x400 field ± S.E. * P<0.05, compared 
to positive staining in blank SMEDDS treated and untreated groups, ANOVA followed 
by post-hoc Newman-Keuls’ testing. 
 
 
 
	  D	  
	   135 
 
 
 
 
Blank  
SMEDDS 
 
 
 
 
 
 
 
 
 
 
Curcumin  
SMEDDS 
 
 
 
 
 
 
 
 
 
 
 
Untreated 
 
 
	  
	  	  	  
	  A	  
	  	  
	  B	  
	  C	  
	   136 
 
 
Figure 3.31. Curcumin SMEDDS treatment decreases microvascularization in 
mammary tumor tissue. Female athymic nude mice bearing MDA-MB-231 human tumor 
xenografts were dosed daily at 100 mg/kg with (A) blank SMEDDS formulation, (B) 
curcumin SMEDDS formulation, or (C) remained untreated. Mice were sacrificed at 2 
months after the initial dose and mammary tissue was stained with anti-CD31 antibody. 
(D) Positive CD31 staining was quantified as percentage stained per field of view at x400 
magnification using ImageJ software. Scale bars represent 100 µm. Data are presented as 
average percentage of CD31 positive staining per x400 field ± S.E. * P<0.05, compared 
to positive staining in blank SMEDDS treated and untreated groups, ANOVA followed 
by post-hoc Newman-Keuls’ testing. 
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Figure 3.32. Curcumin SMEDDS treatment increases apoptosis in mammary tumor 
tissue. Female athymic nude mice bearing MDA-MB-231 human tumor xenografts were 
dosed daily at 100 mg/kg with (A) blank SMEDDS formulation, (B) curcumin SMEDDS 
formulation, or (C) remained untreated. Mice were sacrificed at 2 months after the initial 
dose and mammary tissue was stained with anti-caspase-3 antibody. (D) Positive caspase-
3 staining was quantified as percentage stained per field of view at x400 magnification 
using ImageJ software. Scale bars represent 100 µm. Data are presented as average 
percentage of caspase-3 positive staining per x400 field ± S.E. * P<0.05, compared to 
positive staining in blank SMEDDS treated and untreated groups, ANOVA followed by 
post-hoc Newman-Keuls’ testing. 
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 The primary goal of this dissertation is to evaluate the chemopreventive potential 
of orally dosed curcumin in breast cancer based on the prodrug activation hypothesis. 
According to the prodrug hypothesis, orally administered curcumin that is absorbed along 
the gastrointestinal tract is rapidly metabolized to form curcumin glucuronide. The 
inactive glucuronide metabolite present in systemic circulation is then either re-activated 
back to active curcumin by β-glucuronidase present at high concentrations at the tumor or 
inflammation site, where it may exert its pharmacological effects, or is renally 
eliminated. A self-microemulsifying drug delivery system (SMEDDS) formulation was 
employed for the oral dosing studies to improve curcumin absorption in the gut. The 
studies in this thesis investigated several aspects of the prodrug hypothesis to elucidate its 
validity, including quantifying β-glucuronidase expression levels and specific activity 
according to the stage and subtype of breast cancer, determining the chemopreventive 
efficacy, evaluating the potential for curcumin accumulation in tumor tissue, and 
analyzing pharmacokinetics of both curcumin and curcumin glucuronide.  
 
Two key questions were posed that set the stage for these studies:  
 
1.) How does oral curcumin exhibit chemopreventive and therapeutic activity despite 
not being absorbed into the systemic circulation in its active form?  
2.) Is the inactive metabolite curcumin glucuronide a natural prodrug? 
 
The prodrug activation hypothesis proposes to explain the mechanisms behind this 
‘bioavailability paradox.’ That is, this hypothesis is a potential explanation for the 
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seemingly paradoxical phenomenon that despite the less than 1% bioavailability of oral 
curcumin due to its poor intestinal absorption and extensive metabolism, curcumin still 
exhibits numerous health and therapeutic benefits when administered orally.  
 In the initial studies, β-glucuronidase expression levels were determined 
according to breast cancer stage and subtype in human breast carcinoma tissue, which 
were surgically resected from patients to form a tissue microarray for multiplexed 
histological analysis. Tumors at the most advanced stage of development and HER-2+ 
subtype tumors had the highest expression levels of β-glucuronidase among all other 
subtypes due most likely to its aggressive nature and hence greater recruitment of 
immune cells such as macrophages and neutrophils, which are responsible for liberating 
β-glucuronidase into the extracellular matrix [110]. Similar is the logic for the most 
advanced stages of tumorigenesis to yield the highest levels of β-glucuronidase 
expression. As the tumor grows in size, there is an increased tendency for it to develop a 
dysregulated vasculature [181]. Thus, large tumors tend to be hypoxic, causing tumor 
cells in these central hypoxic regions to die and form a necrotic core [114, 181]. These 
regions of tumor necrosis are largely responsible for high infiltration of monocytes 
(macrophages) and granulocytes (neutrophils) in response to the associated increased 
levels of inflammation in necrotic regions [114], hence the greater levels of β-
glucuronidase within larger, more advanced tumors.  
 Based on our histological studies, it is clear that β-glucuronidase is overexpressed 
in human adenocarcinoma as compared to normal tissue. Enzyme expression levels were 
highly variable based on the subtype and stage of the mammary tumor. Malignant HER-
2+ breast cancer tumors were predicted to yield the highest β-glucuronidase specific 
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activity, and hence may potentially benefit the most from prodrug administration and 
release of the active compound at the desired site of action. Since it was established that 
β-glucuronidase overexpression occurred in human tissue and that levels were variant, the 
next set of studies aimed at determining β-glucuronidase expression and specific activity 
levels in vitro, both in cell culture and in tissue from animal models. 
 In vitro experiments that aimed to quantify β-glucuronidase activity levels in 
breast carcinoma cells in culture (intact and lysed cells) that were subjected to either 
normal atmospheric conditions or hypoxic (< 5% O2) conditions showed no detectable 
levels of β-glucuronidase activity. MDA-MB-231 cells were subjected to hypoxic 
conditions to mimic the conditions found in the tumor microenvironment and to 
determine whether hypoxia would affect the β-glucuronidase expression and activity 
levels within these cells. No intracellular β-glucuronidase activity was observed in any of 
the six adenocarcinoma cell lines of HER-2+, triple negative, and ER/PR+ type 
originating from both human and mouse species. These results suggest that β-
glucuronidase is present extracellularly, and that the activity by β-glucuronidase occurs in 
the extracellular matrix. This makes sense, as infiltration of macrophages and neutrophils 
occurs into the extracellular matrix of the tumor [114], from which β-glucuronidase 
would be liberated. While it is known that there is some inherent β-glucuronidase activity 
in the lysosomes of all mammalian cells [104], the overexpressed enzyme levels present 
in the extracellular matrix likely is much greater than what is present within the cell.  
 Prior to conducting experiments to determine β-glucuronidase expression and 
specific activity as a function of breast cancer stage, subtype, and tumor model, two 
preliminary studies were performed to confirm the activity of β-glucuronidase within the 
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tumor. β-glucuronidase activities were determined by monitoring 4-Nitrophenyl β-D-
glucuronide (NPG) conversion to parent 4-Nitrophenol (NP). The first study sought to 
ensure that β-glucuronidase was in fact the enzyme that was cleaving the glucuronide 
moiety to yield the active parent compound. Saccharolactone, a known inhibitor of β-
glucuronidase [182], proved to effectively inhibit the activity of β-glucuronidase in 
mammary tumor tissue homogenate from Balb-neuT transgenic mice (Figure 3.8). This 
not only confirmed that β-glucuronidase was the enzyme responsible for glucuronide 
activation to the parent compound, but that the decrease in NPG levels with the 
proportional increase in NP levels was not due to natural or spontaneous degradation of 
the glucuronide compound. The second study showed that the glucuronide compound is 
activated to the parent drug compound only in the tumor where β-glucuronidase is 
overexpressed, and not in the plasma while the glucuronide is in systemic circulation 
(Figure 3.7). This is crucial, as the prodrug hypothesis holds only if the glucuronidated 
drug remains inactive and intact in the plasma, but is then activated specifically within 
the tumor or inflammatory site by β-glucuronidase.  
 β-glucuronidase expression and specific activity levels were quantified in 
mammary tumors in transgenic female Balb-neuT mice at 5 different age groups – 3, 8, 
12, 16, and 23 weeks – to represent each progressive stage of tumorigenesis. The Balb-
neuT model mimics the complex interplay between the developing mammary tumor and 
the host immune system by forming autochthonous tumors from a single cell [171], and 
so this model is representative of the HER-2+ type breast cancer found in human patients. 
Western blotting was used to determine normalized enzyme expression levels in tumor, 
and β-glucuronidase activity assays that monitor NPG conversion to parent NP were 
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conducted to determine specific activities. Interestingly, both enzyme expression and 
specific activity followed nearly identical trends. The trend in the β-glucuronidase 
expression as determined by Western blotting was similar to that of the β-glucuronidase 
specific activities in the same age groups. This shows that β-glucuronidase expression 
correlates closely with specific activity levels. The greater the levels of β-glucuronidase 
present within the tumor or disease site, the higher the specific activity. Expression levels 
and specific activities were the lowest at 3 weeks of age when the mammary glands were 
hyperplastic [171], and both gradually increased with the progression of tumorigenesis as 
tumors developed from hyperplastic to in situ carcinoma to invasive carcinoma, until 
finally at the most advanced stage of metastasis at 23 weeks of age. Because of higher 
levels of β-glucuronidase present, these advanced stages would be more prone to activate 
greater amounts of glucuronidated prodrug at the target site. 
The slightly elevated β-glucuronidase specific activity levels observed at 12 
weeks of age as compared to at 16 weeks in this model may be due to multiple reasons. 
At 6-10 weeks, microvessel density and growth tends to be increased, along with levels 
of growth factors (i.e., VEGF, FGF) and pro-inflammatory cytokines [171]. By 
approximately 15 weeks, microvasculature is lessened in density and growth factor levels 
are decreased as compared to at 5-8 weeks of age [172]. This is the stage when carcinoma 
in situ progresses to becoming invasive. Previous studies have shown that 13 weeks of 
age is a critical stage in Balb-neuT tumorigenesis, in that treatment with curcumin 
SMEDDS prior to 13 weeks has shown efficacy in reducing tumor growth rate, whereas 
after 13 weeks, curcumin treatment showed little to no effect [183]. Specific activity 
proved to be the highest at the most advanced stage of tumorigenesis (metastasis) at 23 
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weeks, showing that the greater the tumor aggression and stage, the higher the β-
glucuronidase specific activity. 
The overexpression of β-glucuronidase in the transgenic tumor model is further 
reiterated by the higher specific activity levels in each of the stages of tumorigenesis of 
the Balb-neuT model as compared to the activities in wild-type mammary tissue from 
mice of the same age groups (Figure 3.6). It is noteworthy that even at 3 weeks of age, 
when the mammary cells in the Balb-neuT model are hyperplastic, the specific activity of 
β-glucuronidase is already greater (2.58 ± 0.72 nmol NP formed/hr/mg protein) than that 
of healthy mammary tissue (0.74 ± 0.40 nmol NP formed/hr/mg protein) from wild-type 
Balb/c mice of the same age. This may be due to the genetic predisposition of mammary 
tumors to form in the Balb-neuT model at such a nascent age, and so this is reflected in 
the immune cell infiltration of macrophages and neutrophils of the tumor and therefore β-
glucuronidase activity is increased as a result.  
 
 In addition to quantifying β-glucuronidase specific activity levels in the 
transgenic Balb-neuT model and correlating them with enzyme expression, the next set of 
studies aimed at quantifying specific activities in orthotopic mammary tumor models: JC, 
TuBo, MDA-MB-231, and 4T1. Of the four models, TuBo showed the lowest β-
glucuronidase specific activity in all tumor volumes when compared to that of the MDA-
MB-231, JC, and 4T1 models, which all had comparable activities. This is despite the 
fact that TuBo cells are HER-2 overexpressing cells. According to the 
immunohistochemistry studies with the human mammary tissue microarray, HER-2+ 
type tissues showed the highest levels of β-glucuronidase expression, but these activity 
	   146 
data with TuBo seems to contradict this generalization of HER-2+ tissue having the 
highest expression levels of β-glucuronidase enzyme. The low specific activity observed 
in TuBo may be due to minimal macrophage and neutrophil immune cell infiltration 
within the tumor tissue of this model [114]. These results support that β-glucuronidase 
activity levels are not only linked to breast cancer subtype alone, but other factors such as 
immune cell infiltration also play a crucial role.  
 One additional point to highlight when comparing enzyme specific activities 
across the orthotopic models is that the levels of β-glucuronidase activity plateau off at 
volumes above 400 mm3. While the actual amount of increase in specific activity from 
volume to volume is variable between models (lower in TuBo and higher in the other 3 
models), the percent increase in activity is comparable across the 4 models. This 
“plateauing” of specific activities beyond a tumor volume of 400 mm3 is important to 
note, as the pharmacokinetic and curcumin accumulation studies are based on this fact. In 
these studies, since the β-glucuronidase specific activity is similar and does not increase 
significantly as the tumor grows beyond 400 mm3, this was the tumor volume chosen to 
begin oral dosing of the curcumin microemulsion formulation. It should be noted that 
most tumor inhibition and drug accumulation studies start the treatments when tumors are 
relatively small (~100 mm3). In general, smaller tumors respond better to treatments than 
larger ones [184]. Thus, the fact that oral curcumin significantly accumulates in the tumor 
even when the treatment was started at a later stage in tumor growth is particularly 
noteworthy. 
 Since the 4T1 model is the most aggressive of the 4 models in the study and is 
prone to metastasis to distant sites at later stages of development, lungs were collected in 
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addition to the tumor in order to determine specific activity in these tissues as well. 
Results showed that while specific activities were lower in lungs than in tumor in 4T1, 
the specific activity of the lungs from the 4T1 model was significantly higher than the 
activity of lungs from the wild-type model. These results show that metastatic tumors at 
distant sites – in this case, the lungs – also have increased expression of β-glucuronidase. 
This suggests that curcumin glucuronide activation could occur not just in the tumor but 
also at the metastatic sites.  
 Based on these results, chemopreventive efficacy studies were performed to 
elucidate the effects of oral curcumin on inhibiting tumor growth. In the 4T1 model, the 
average volume of the curcumin SMEDDS group was significantly lower only when 
compared to the average volume of the blank SMEDDS group after one month; there was 
no statistical difference between the average volumes of the curcumin SMEDDS and 
untreated groups. This is due most likely to the aggression of the model itself [185], and 
not to the specific activity of β-glucuronidase present within the tumor. Though it is 
evident that some level of β-glucuronidase activity is present, as seen with the lower 
volume of the curcumin SMEDDS treated group in comparison with the blank SMEDDS 
treated group, the aggression of 4T1 may potentially overcome the therapeutic effects of 
curcumin. In JC and MDA-MB-231, for example, the tumor growth is less aggressive, 
and so curcumin delivery results in a therapeutic benefit. In the TuBo model, however, 
there was no significant difference in tumor volumes between the treatment groups. This 
is attributable to the low specific activity levels of β-glucuronidase in TuBo mammary 
tumors, as determined from the activity assays. These results strongly support the notion 
	   148 
that orally administered curcumin in a microemulsion formulation has an efficacious 
effect on limiting tumor growth rate based on the prodrug activation hypothesis. 
 It is important to note that the tumor growth rate inhibition is dependent not only 
on β-glucuronidase specific activity, but also on the tumor cell sensitivity to curcumin. 
Interestingly, of the 4 cell lines, TuBo cells showed the greatest resistance to curcumin 
treatment in vitro. Thus, in addition to the limited conversion of curcumin glucuronide to 
active curcumin in the extracellular matrix of the tumor, the inherent resistance of the 
TuBo cells to curcumin resulted in poor efficacy of orally delivered curcumin in this 
tumor model.  
 
 In addition to measuring β-glucuronidase specific activity ex-vivo in extracted 
tumor tissue from various mouse models, activity levels were also determined in vivo in 
an MDA-MB-231 LM2 (or LM2) model using an activity-based near-infrared fluorescent 
difluoromethylphenol-glucuronide probe. Fluorescence imaging was used to determine 
levels of β-glucuronidase expression and activity based on enzyme activity in vivo. The 
glucuronidated probe is non-fluorescent; however, when the glucuronide is cleaved by β-
glucuronidase in the tumor and the fluorescent probe is released, fluorescence can be 
detected by the imager [180]. According to the results, an increase in fluorescence was 
observed with increasing tumor volume in the LM2 model, indicating that β-
glucuronidase activity is present in activating the fluorescent parent probe by cleaving the 
glucuronide. 
 According to the ex-vivo studies determining β-glucuronidase specific activity in 
the JC, 4T1, MDA-MB-231, and TuBo models, specific activity increases from 100 mm3 
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to 400 mm3, but then plateaus at volumes higher than 400 mm3. Since this trend was 
observed in all 4 models studied, this most likely occurs in the LM2 model as well. Thus, 
in the LM2 model in these in vivo imaging studies, it may also be that enzyme specific 
activity increases initially at smaller tumor volumes, but at larger tumor volumes, the 
activity would remain practically constant. The higher levels of fluorescence observed in 
the larger tumor sizes, then, would mainly be due to increased levels of β-glucuronidase 
in the tumor. Imaging studies do not allow for estimation of specific activity of the 
enzyme in the tumor. The main goal of these imaging studies was to show a visual 
representation of the presence of β-glucuronidase activity in the tumor of live animals. 
 One point to highlight in these in vivo imaging studies is the considerable level of 
fluorescence that occurs in the liver in the more advanced stages of tumor growth, such as 
at tumor volumes of 700 mm3 and 1200 mm3. This may suggest an elevated β-
glucuronidase activity in the liver or the presence of metastases in the liver. This, 
however, was unlikely because fluorescence in the liver region was observed even when 
the tumor was in the earliest stages of development (100 mm3 in size) but not in healthy 
animals. Furthermore, no fluorescence was observed in the lungs, the major site of 
metastasis for the LM2 cells. The most likely cause of fluorescence in the liver region 
even from the earliest stages of tumorigenesis is the potential re-circulation of the 
fluorescent probe after activation by β-glucuronidase in the tumor. Clearance of the 
fluorescent probe from the tumor into the systemic circulation would result in significant 
levels of the probe accumulating in the liver, one of the major eliminating organs. As 
tumor volume increases, the fluorescence in liver increases in correlation with that in the 
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tumor, indicating greater levels of fluorescent probe re-circulating after having been 
activated by β-glucuronidase at the tumor site.   
 
 The next set of studies investigated the pharmacokinetics of curcumin and its 
metabolite curcumin glucuronide following either oral dosing of curcumin SMEDDS or 
intravenous dosing of curcumin glucuronide in the 4T1 and TuBo models. The ultimate 
goal of these studies was to correlate the curcumin levels generated in the tumor with the 
β-glucuronidase specific activity in that tumor type. The two models were chosen 
specifically for their high (4T1) and low (TuBo) specific activities of β-glucuronidase. 
The plasma levels of curcumin glucuronide following oral dosing of curcumin SMEDDS 
far exceeded the levels of the parent curcumin compound itself, indicating that curcumin 
undergoes rapid first-pass metabolism upon absorption from the gut. In tumor, however, 
curcumin levels were far greater than that of curcumin glucuronide. Curcumin 
concentrations in 4T1 tumors were greater than in TuBo tumors. These results point to 
the strong correlation between curcumin generation and the β-glucuronidase specific 
activity. 
 Curcumin concentrations in liver were highly variable in both models. This may 
very well be due to the high variability in curcumin absorption from the gastrointestinal 
tract. Despite receiving the same dose (100 mg/kg), absorption rates of curcumin from 
the gut may be wide ranging, which would result in minimal to excessive amounts of 
curcumin present in the liver at a given point in time. It is interesting to note, however, 
that despite this variance in liver curcumin concentrations from animal to animal, the 
concentration-time profiles for curcumin glucuronide in plasma and curcumin in tumor 
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follow distinct trends and are typical of what would be observed in a pharmacokinetic 
profile of drug concentrations in plasma and target tissue following oral dosing. In other 
words, since curcumin concentrations are highly variable in liver, it is intriguing that the 
curcumin and metabolite concentrations in plasma and tumor do not follow similarly 
scattered profiles. One reason for this could be that despite the variable concentrations, 
the liver may metabolize curcumin at only a certain maximal rate, and so any excess 
curcumin may be eliminated by enterohepatic recirculation from the liver back into the 
gastrointestinal tract. The gut may absorb far more curcumin than what the liver is 
capable of metabolizing. According to the results, the maximal concentration of curcumin 
glucuronide in plasma following intravenous dosing is ~ 65 – 70 µg/mL, the extrapolated 
initial concentration of glucuronide at time zero. Thus, in addition to the glucuronidation 
that takes place in the enterocytes along the gastrointestinal wall, the liver would 
theoretically only need to be presented with enough curcumin from the portal vein in 
order to metabolize and produce combined curcumin glucuronide concentrations of  ~ 65 
– 70 µg/mL in plasma following oral dosing. 
 Curcumin tumor disposition was rather interesting. In both the 4T1 and TuBo 
models, the curcumin concentrations in tumor following oral dosing was slightly elevated 
as compared to that at the 4-hour time point. This suggests the potential for slow and 
sustained curcumin accumulation in tumor from even a single oral dose. In a typical 
pharmacokinetic profile following oral dosing, once Cmax (absorption rate = elimination 
rate) has been reached and the elimination rate becomes greater than the absorption rate, 
drug concentrations in the plasma and tissue begin to steadily decline at a linear rate (i.e., 
elimination phase). This explains the decline in curcumin levels from Cmax at 1 hour to 4 
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hours post-dose in both models. However, with the oral dosing of curcumin, the drug 
concentration is lowest at the 4-hour time point, and then increases again at the 8-hour 
time point. This is could be due to redistribution of curcumin and/or glucuronide from 
other tissue sites (i.e., liver and lungs) to the tumor. Curcumin glucuronide was still 
present in the plasma even after 8 hours post-oral dose (~8 µg/mL), and so a constant and 
steady supply of glucuronide to the tumor site was available between 4 and 8 hours post-
dose. With the half-life of curcumin elimination from tumor as calculated by non-
compartmental analysis to be at 40.5 hours, curcumin would steadily accumulate in the 
tumor, given that glucuronide is still presented by circulation and β-glucuronidase 
continues to activate the metabolite back to curcumin within the tumor. In terms of rates, 
the absorption rate of curcumin into the tumor (conversion of curcumin glucuronide to 
curcumin) and elimination rate of curcumin from the tumor (clearance of curcumin from 
tumor) remain constant, but since absorption rate > elimination rate (low due to longer 
elimination half-life), curcumin levels in tumor would accumulate until eventually the 
plasma levels of the glucuronide decline.  Additional studies examining the disposition of 
curcumin and its metabolite beyond 24 hours are needed to confirm these findings. 
 The second study sought to determine the pharmacokinetic parameters of just the 
metabolite, curcumin glucuronide, and confirm the values with those determined from the 
curcumin glucuronide formed endogenously by first-pass metabolism in the first study. 
This study involved the intravenous dosing of glucuronide so as to bypass the absorption 
barrier that would occur with oral dosing. The resulting concentration-time profiles of 
curcumin glucuronide following IV dosing of the metabolite were practically identical 
between the 4T1 and TuBo models. Non-compartmental analysis by Phoenix WinNonlin 
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6.3 (Pharsight, St. Louis, MO) of the pharmacokinetic parameters revealed the half-life of 
curcumin glucuronide elimination from plasma (t1/2 = 3.9 hours) to be the same, whether 
the glucuronide was formed endogenously following oral dosing of curcumin or 
intravenously dosed directly into the systemic circulation. In addition, a third study in 
which glucuronide was dosed intravenously into healthy, tumor-free, wild-type female 
mice of the same age yielded a similar half-life of elimination. Because the 
pharmacokinetic parameters were the same for curcumin glucuronide in plasma across 
these three studies, it was concluded that the route of administration and the disease 
status of the animal model did not have an effect on the glucuronide biodistribution in 
circulation.  
 Curcumin concentrations in the tumor of 4T1 and TuBo were greater than that of 
what was seen in the mammary tissue of wild-type mice. This was the case with both the 
oral dosing of curcumin SMEDDS and the intravenous dosing of curcumin glucuronide. 
These observations strongly support the prodrug hypothesis not only in the sense that 
curcumin levels are significantly higher in tumor despite curcumin glucuronide being the 
predominant form present in plasma, but the concentration levels of curcumin are 
elevated in the tumor models as compared to in the wild-type model. Increased β-
glucuronidase activity due to elevated levels of the enzyme in the tumor increases the rate 
at which curcumin glucuronide is converted to active curcumin, and thus increased 
concentrations of curcumin are present in the tumor microenvironment. Since the specific 
activity of enzyme is lower in mammary tissue of healthy mice due to minimal 
expression of β-glucuronidase, it follows that the glucuronide activation rate would 
consequently be lower and hence lower levels of curcumin would be formed in the tumor.  
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The prodrug activation hypothesis is well supported by the results from multiple 
oral dosing and pharmacokinetic studies: curcumin glucuronide levels in plasma far 
exceed that of curcumin itself, glucuronide plasma levels were relatively the same 
between the wild-type and the tumor models, curcumin levels in tumor were much 
greater than glucuronide levels, and curcumin concentrations were by far significantly 
higher in the tumor from the 4T1 model than in the mammary tissue from the wild-type 
model. Curcumin is a hydrophobic polyphenolic compound, and is therefore capable of 
tissue accumulation over an extended period of time of regular dosing. It is interesting to 
note that while curcumin accumulation was evident in both the orthotopic TuBo and JC 
models after one month of daily oral dosing with curcumin SMEDDS, accumulation 
levels in TuBo tumors were significantly higher than in JC tumors. This can be explained 
by the potential higher infiltration levels of macrophages and neutrophils to the tumor site 
in the TuBo model as compared to that of JC. Curcumin concentration in 4T1 tumor after 
two weeks of daily oral dosing was significantly higher than that achieved after a single, 
one-time oral dose. Tumor volumes were 400 mm3 at the time of initiating the oral dosing 
in both the single and multiple dosing groups so that β-glucuronidase specific activity 
levels would be comparable. In the multiple dosing group though, since the treatments 
were given for 14 consecutive days, the average tumor size in this group increased to 
approximately 700 mm3 by the end of the study, which may have had an impact on the β-
glucuronidase specific activity. However, our studies show that the enzyme activity in 
4T1 tumors plateau after having reached 400 mm3 in volume, and so tumor volumes 
greater than 400 mm3 have comparable levels of activity as tumors that are 400 mm3 in 
size. Therefore, it was concluded that the higher tumor curcumin levels in the multiple 
	   155 
dosing group was due to curcumin accumulation, and not because of elevated β-
glucuronidase specific activity as a result of larger tumor volumes at the end of the study.  
Previous studies have shown that regular, low-dose drug treatments have greater 
therapeutic effects than dosing high concentrations of drug for a shorter duration. This 
concept has been termed as “metronomic treatment” [75, 76]. Conventional treatments 
such as chemotherapy are high-dose and acute, resulting in the direct killing of cancer 
cells and potentially the surrounding healthy cells, causing undesirable side effects. 
However, with metronomic treatment, sustained, low levels of drug are maintained in the 
systemic circulation, and so the drug is able to exert its pharmacological effects at the 
targeted site of action over an extended period of time. The results of the efficacy and 
accumulation studies suggest that daily oral dosing of curcumin SMEDDS generates 
small quantities of curcumin for a prolonged period of time, and this is effective in 
inhibiting tumor growth. Thus, our data supports the notion of “metronomic 
chemoprevention” by curcumin.  
 
 Curcumin is known to regulate numerous signal transduction pathways that affect 
cell proliferation, angiogenesis, and apoptosis. Previous studies have shown that 
curcumin limits cell proliferation [54] and angiogenesis [52, 53], and induces apoptosis 
[55], all of which are important for inhibiting tumor growth. In the current studies, the 
effect of curcumin on three biomarkers – Ki-67 (cell proliferation), CD31 (angiogenesis), 
and cleaved caspase-3 (apoptosis) – were studied. Tumor tissue from the MDA-MB-231 
model was chosen because it had the greatest response to curcumin treatment, as shown 
from the efficacy studies.  
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Results from these studies showed statistically significant differences in the levels 
of all 3 biomarkers from the curcumin SMEDDS treated group as compared to the blank 
SMEDDS and untreated control groups. There was a significantly lower level of staining 
for Ki-67 and CD31 in the curcumin treated group as compared to the other control 
groups, indicating that curcumin does exert an effect in limiting tumorigenesis by 
decreasing cell proliferation and the microvessel density within the tumor. It is interesting 
to note that levels of Ki-67 and CD31 were slightly elevated in the blank SMEDDS 
treated group as compared to the untreated group. This is most likely because of one of 
two reasons, or potentially a combination of both: 1.) blank SMEDDS formulation free of 
drug could in itself induce some levels of increased cell proliferation and angiogenesis, or 
2.) animals treated with blank SMEDDS were subjected to increased levels of stress from 
handling and oral gavage procedures, thus promoting cell proliferation and 
microvasculature increase. Despite this, the presence of curcumin ultimately lowers cell 
proliferation and decreases angiogenesis in the tumor microenvironment. 
 Curcumin treatment elevated cleaved caspase-3 levels. Cleaved caspase-3 is a 
marker for cell apoptosis, and curcumin is known to induce tumor cell apoptosis. These 
effects of curcumin are apparent on a larger scale as well in the chemopreventive efficacy 
study, in that MDA-MB-231 tumors from the curcumin SMEDDS treated group were 
less than half the volume of those from the blank SMEDDS or untreated group after two 
months of receiving such treatments. The results from these immunohistological studies 
further confirm the chemopreventive efficacy of orally dosed curcumin at a cellular level. 
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 Numerous reports in literature have correlated β-glucuronidase overexpression in 
inflammatory and tumor tissue with its specific activity and therapeutic potential in 
activating prodrugs to increase drug specificity to the disease site [121-127]. Previous 
studies have shown that necrotic regions of tumors that are highly infiltrated with 
immune response cells such as macrophages and neutrophils reveal the greatest levels of 
β-glucuronidase upregulation [121]. In other studies, β-glucuronidase expression and 
specific activity levels were determined to be lowest in healthy pancreatic tissue and 
highest in pancreatitis and pancreatic adenocarcinoma tissue, as determined by activity 
assays that monitored MUG to parent MU conversion [122]. Other reports have studied 
specifically the therapeutic potential of prodrug forms of various chemotherapeutic 
compounds – specifically irinotecan, or CPT-11 [123], and doxorubicin [124] – 
according to the increased specific activity of β-glucuronidase in disease pathology. It 
was determined in these studies that healthy normal tissues that expressed marginal levels 
of β-glucuronidase yielded negligible levels of active SN-38 and doxorubicin, whereas in 
inflammatory and tumor tissue, the increased levels of β-glucuronidase resulted in higher 
levels of active drug being present at the target site. Additionally, efficacy in inhibiting 
tumor growth was observed to be increased in EJ/mβG tumor-bearing mice as compared 
to in mice bearing wild-type EJ tumors that do not overexpress β-glucuronidase when 
both groups were treated with the endogenously glucuronidated drug CPT-11 [125]. 
These previous reports illustrate the potential for the natural phenomenon of β-
glucuronidase overexpression in the malignant tissue to be employed as a therapeutic 
approach to improving drug delivery. 
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 The data and results presented in this thesis highly correlate with what has been 
previously reported in literature, and further reinforces the notion that β-glucuronidase 
overexpression in inflammatory and tumor tissue can be exploited for therapeutic benefit. 
One of the goals of the work here was to determine whether β-glucuronidase would be 
upregulated in breast cancer, and if so, would this type of cancer also respond to 
treatments that would involve the activation activity of β-glucuronidase as described in 
the literature. It was determined from our studies that β-glucuronidase is indeed 
overexpressed in several mammary tumor models as well, and that treatment with a 
polyphenol that is known to be highly glucuronidated results in significant efficacy based 
on β-glucuronidase expression and activity at the tumor site. The results from this thesis 
work are in strong agreement with previous reports [122-126], in that mammary tumors 
express minimal levels of β-glucuronidase at initial stages of tumorigenesis but levels 
increase significantly as the disease progresses, specific activity is highly correlated with 
enzyme expression levels, and efficacy in limiting tumor growth rate is exhibited based 
on the enzymatic activation activity of β-glucuronidase at the tumor site.   
 These studies with curcumin, a relatively non-toxic, dietary polyphenolic 
molecule, have the potential to have global implications in being applied to other 
chemopreventive agents that can be targeted to specifically the tumor site following oral 
administration. Since many other chemopreventive compounds undergo glucuronidation 
[187-190], the research presented here could very well serve as a model for future studies 
involving the evaluation of other dietary compounds for therapeutic efficacy and 
chemoprevention. These studies, based on the prodrug hypothesis, would suggest that for 
a chemopreventive agent that has poor bioavailability and low plasma concentrations but 
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exhibits efficacy, the concentration of inactive metabolite in plasma should be evaluated 
as an indicator of efficacy rather than that of the active parent compound. The 
applicability of these promising results that support the prodrug hypothesis, in 
combination with β-glucuronidase activity typically being upregulated during 
inflammation, could potentially not only transform the field of cancer chemoprevention, 
but also impact a wide array of inflammatory diseases in general.  
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Curcumin, a naturally occurring polyphenol derived from turmeric, has been 
shown to possess anti-cancer and anti-inflammatory effects, and hence chemopreventive 
potential in epidemiological studies. However, curcumin has poor bioavailability (<1%) 
due to low absorption and rapid first-pass metabolism. The main objective of this thesis 
was to examine and evaluate the validity of an enzymatic prodrug activation hypothesis 
that proposes to explain this ‘bioavailability paradox.’ According to the hypothesis, the 
inactive glucuronide metabolites are naturally occurring prodrugs of curcumin that are 
selectively activated only in the tumor site to generate the active parent compound. β-
glucuronidase, an enzyme that hydrolyzes the glycosidic bond of glucuronides, is of 
primary interest in these studies, as this hypothesis posits that β-glucuronidase generates 
the active agent from the glucuronide metabolites ‘on demand’ at the required sites of 
action, such as in tumor or sites of inflammation. 
The objective of the first set of studies was to determine the relationship between 
disease stage/tumor subtype and β-glucuronidase activity in human and mouse mammary 
tumors. Based on immunohistochemistry studies with human mammary adenocarcinoma 
tissue of varying stages and subtypes, advanced stage and HER-2+ subtype tumors 
showed the highest levels of β-glucuronidase overexpression. Normal and benign stages 
of tumor showed the lowest levels of β-glucuronidase while the invasive/metastatic stage 
showed the highest levels. It was observed, however, that of the 4 orthotopic mammary 
adenocarcinoma models (JC, TuBo, MDA-MB-231, 4T1) studied, TuBo, a HER-2+ 
overexpressing model, had the lowest β-glucuronidase specific activity, while 4T1, a 
triple negative subtype model, had the greatest enzymatic specific activity. Moreover, 
since 4T1 is an aggressive model that is prone to metastasis, lungs from the advanced 
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stages of tumorigenesis in this model also showed elevated β-glucuronidase levels as 
compared to lungs from healthy, wild-type mice, suggesting that these distant sites may 
also be susceptible to curcumin intervention.  
β-glucuronidase expression and activity levels were also determined in the 
transgenic Balb-neuT model, in which levels were compared both between the stages of 
tumorigenesis as well as between the Balb-neuT model and the wild-type Balb/c model. 
Once again, the results from these studies reiterated that β-glucuronidase expression and 
activity levels increase with successive stages in tumor development and that β-
glucuronidase is overexpressed in inflammatory and tumor tissue as compared to healthy 
tissue. With each progressive stage of tumorigenesis in Balb-neuT, the enzyme 
expression levels gradually increased, as shown from Western blotting studies, and 
specific activities of β-glucuronidase also increased in correlation, as seen in the enzyme 
activity assays. Fluorescent imaging studies with the MDA-MB-231 LM2 model 
presented a visual representation of β-glucuronidase activity in vivo, and further 
confirmed that enzyme activity increases with tumor growth and volume.  
We next sought to investigate the role of β-glucuronidase activity in the 
chemopreventive efficacy of oral curcumin. The orthotopic models that were evaluated in 
the β-glucuronidase expression and activity studies showed therapeutic efficacy from oral 
curcumin treatment, with the exception of the TuBo model. Aside from the low levels of 
β-glucuronidase activity in TuBo, it was also determined that TuBo cells were inherently 
resistant to curcumin treatment, giving further reason to the limited efficacy of curcumin 
treatment in this model. In the 4T1 model, despite the high β-glucuronidase activity that 
was observed from the specific activity assays, efficacy was not the highest, as would be 
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expected with 4T1. This can be explained by the aggression of the 4T1 model, which 
may in fact overcome the therapeutic effects of curcumin treatment. MDA-MB-231 was 
the model that showed the most promising results, in that efficacy data strongly 
correlated with the significant specific β-glucuronidase activity seen in this model. Based 
on immunohistological analysis of Ki-67, CD31, and caspase-3, it was determined that 
curcumin significantly reduces cell proliferation, tumor vasculature size and density, and 
induces apoptosis. These results hold great potential since MDA-MB-231 is an orthotopic 
human xenograft model, making this study potentially more translatable to the clinic. 
The final set of studies aimed to evaluate the pharmacokinetics and drug 
accumulation of curcumin and curcumin glucuronide in both wild-type and tumor-
bearing mouse models. The 4T1 and TuBo orthotopic models were used for these 
pharmacokinetic studies due to their respective high and low β-glucuronidase specific 
activities, as determined from the activity assay studies. Data from these studies showed 
that curcumin glucuronide levels in plasma were much greater than that of curcumin 
itself following oral dosing of curcumin SMEDDS, curcumin levels in tumor far 
exceeded that of glucuronide levels, glucuronide plasma levels were practically the same 
between the wild-type and tumor models, and curcumin concentrations in 4T1 tumors 
were significantly higher than in the healthy, mammary tissue from wild-type mice.  
Since curcumin is hydrophobic in nature and is capable of tissue accumulation, 
drug accumulation studies revealed the potential for curcumin to accumulate in the tumor 
tissue of both transgenic (Balb-neuT) and orthotopic (JC, TuBo, 4T1) models. In the 
orthotopic models, evidence of curcumin accumulation following multiple dosing of 
curcumin SMEDDS was present, with 4T1 tumors having accumulated the highest levels 
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and TuBo tumors having accumulated the lowest levels. This is in correlation with their 
respective β-glucuronidase specific activities. In all of the models studied for curcumin 
accumulation, significant levels of curcumin were present in the tumor while levels were 
marginal in the plasma. When accumulation of curcumin in 4T1 tumor was compared 
with that of in mammary tissue of wild-type mice for the same multiple dosing 
timeframe, significantly greater levels of curcumin were present in 4T1 tumors than in 
healthy mammary tissue. Additionally, higher levels of curcumin were found in 4T1 
tumors after multiple dosing of oral curcumin as compared to receiving just a single dose. 
Such findings from both the pharmacokinetic and drug accumulation studies strongly 
support the prodrug activation hypothesis.  
The results from this thesis work convincingly demonstrate the presence of β-
glucuronidase in mammary tumors and point to a potential mechanism of action for 
natural chemopreventives such as curcumin that have poor oral bioavailability but have 
potent chemopreventive activity after oral administration. Our studies show that the 
expression of β-glucuronidase is highly correlated with tumor progression in both human 
and mouse tumors, and that oral administration of curcumin results in significant tumor 
concentrations of the parent compound without detectable levels in plasma, thus 
supporting the central hypothesis. Overall, this research establishes the foundations for 
the validity of the enzymatic prodrug activation hypothesis, which would have important 
implications for how chemopreventives such as curcumin are evaluated. Many other 
natural chemopreventive agents undergo glucuronidation, and so the research in this 
thesis could potentially serve as a model for studies with other dietary chemopreventive 
compounds and have an impact on the treatment strategies for numerous inflammatory 
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diseases. Moreover, results from this thesis will enable the advancement of an effective 
and clinically translatable oral dosing strategy for breast cancer chemoprevention and 
therapy.  
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